1172_CSP 3.0  1 of 81 28 October 2021  
Confidential - Entire Page   
Phase II trial of APR -246 in combination with azacitidine as maintenance 
therapy for TP53  mutated AML or MDS following allogeneic stem cell transplant  
 
Protocol No.:  A19-[ZIP_CODE]  
IND No.:  139738  
  
Principal Investigator:  [INVESTIGATOR_584934], MD  
  
 
 
 
  
Sponsor:  Aprea Therapeutics AB  
 
 
 
  
  
Medical Monitor:   
 
 
 
  
Protocol Version:  3.0 
  
Replaces:  2.0 / 22 May 2019  
  
Date:  28 October 2021  
 
CONFIDENTIAL  
 
This document contains strictly confidential information  and cannot be disclosed or 
used, unless authorized in writing by  [CONTACT_584958].  

1172_CSP 3.0  2 of 81 28 October 2021  
Confidential - Entire Page  INVESTIGATOR’S STATEMENT  
1. I have carefully read this protocol entitled "Phase II trial of APR -246 in combination 
with azacitidine as maintenance the rapy for TP53  mutated AML or MDS following 
allogeneic stem cell transplant " and agree that it contains all the necessary 
information required to conduct the study.  I agree to conduct this study as outlined 
in the protocol.  
 
2. I understand that this study  will not be initiated without approval of the appropriate 
Institutional Review Committee/Independent Ethics Committee (IRB/IEC), and that all 
administrative requirements of the governing body of the Institution will be complied 
with fully.  
   
3. Informed written consent will be obtained from all participating patients in 
accordance with institutional guidelines, FDA requirements as specified in Title 21 
CFR, Part 50, the European Union Directive 2001/20/EC and its associated Detailed 
Guidances, European Un ion GCP Directive 2005/28/EC, the ICH Guideline for Good 
Clinical Practice, Section 4.8, and the terms of the Declaration of Helsinki ( 2013 ). 
 
4. I will enroll patients who meet the protocol criteria for entry.  
 
5. I understand that my signature [CONTACT_584984] (CRF) indicates 
that I have carefully reviewed the complete set of CRFs  and accept full responsibility 
for the contents thereof.  
 
6. I understand that the information presented in this study protocol is confidential, and 
I hereby a ssure that no information based on the conduct of the study will be released 
without prior consent from the Sponsor unless this requirement is superseded by [CONTACT_5212], a Competent Authority of the European Union or 
another Regulatory  Authority.  
Investigator:     
Name:         [CONTACT_10880]:   
    
Address:     
    
Signature:   [CONTACT_1782]:   
    
Sponsor  
Representative:     
Signature:   [CONTACT_1782]:   
  
   
  

1172_CSP 3.0  3 of 81 28 October 2021  
Confidential - Entire Page  TABLE OF CONTENTS  
         Page No.  
 
INVESTIGATOR’S STATEMENT  ................................ ................................ ................  [ADDRESS_768925] 6 Patients  ................................ ................................ . 31 
4.3 Study Stoppi[INVESTIGATOR_2121]  ................................ ................................ .................  32 
4.4 End of Study  ................................ ................................ ................................ .... 32 
1172_CSP 3.0  4 of 81 28 October 2021  
Confidential - Entire Page  4.5 Duration of Therapy  ................................ ................................ ......................  32 
4.6 Trial Discontinuation  ................................ ................................ .....................  33 
4.7 Drug Accountability/Disposition of Clinical Trial Supplies  ........................  [ADDRESS_768926] -transplant Criteria for APR-246 and Azacitidine Treatment  ............  35 
5.2.1  Inclusion Criteria  ................................ ................................ .................  35 
5.2.2  Exclusion Criteria  ................................ ................................ ................  37 
5.3 Withdrawal Criteria  ................................ ................................ ........................  38 
5.3.1  With drawn Subjects  ................................ ................................ ...........  38 
5.4 Noncompliance  ................................ ................................ ..............................  38 
6.0 TREATMENT OF SUBJECTS  ................................ ................................ .......  39 
6.1 Drug Preparation and Administration  ................................ ........................  39 
6.1.1  APR-246 ................................ ................................ ................................  39 
6.1.2  Azacitidine  ................................ ................................ ...........................  39 
6.2 Criteria for Retreatment and Dose Modifications  ................................ ..... 40 
6.2.1  Dose Modifications  ................................ ................................ .............  42 
6.3 Concomitant Treatment  ................................ ................................ ................  46 
6.3.1  GVHD During Therapy  ................................ ................................ ........  46 
6.3.2  CNS Toxicity Management  ................................ ................................  47 
6.3.3  Management of Infection and/or Infestation Event(s)  ..................  47 
6.3.4  Management of Neutropenia with or without Fever  .....................  48 
6.3.5  General Concomitant Medications and Supportive Care 
Guidelines  ................................ ................................ ................................ ....... 48 
6.3.6  Prohibited Therapy  ................................ ................................ .............  49 
6.3.7 Other Concomitant Treatment (Medication and Non -
medication Therapy)  ................................ ................................ .....................  [ADDRESS_768927] Compliance  ................................ ................................ ... 50 
7.0 STUDY EVALUATIONS  ................................ ................................ ..............  51 
7.1 Pre-Scre ening  ................................ ................................ ................................ . 51 
7.1.1  Pre-Screening (Day -[ADDRESS_768928])  ................................ .... [ADDRESS_768929] -Transplant, APR -246 Screening Period (Day 1 to 100)  ..........  51 
7.1.4  Confirmation to Proceed to APR -246 and Azacitidine Treatment 
1172_CSP 3.0  5 of 81 28 October 2021  
Confidential - Entire Page  (Day  30 to 100)  ................................ ................................ ...............................  52 
7.2 APR-246 and Azacitidine Treatment  ................................ ............................  52 
7.2.1  Cycle 1, Day 1  ................................ ................................ ......................  52 
7.2.2  Cycle 1, Days 2, 3, 4, 5  ................................ ................................ ........  53 
7.2.3  Cycle 1, Days 7, 14, 21  ................................ ................................ ........  53 
7.2.4  Cycle 1, Day 28  ................................ ................................ ....................  53 
7.2.5  Cycles 2 -4, Day 1 (Day 29 of prior cycle)  ................................ ..........  53 
7.2.6  Cycles 2 -4, Days 2, 3, 4, 5  ................................ ................................ ... 54 
7.2.7  Cycles 2 -4, Day 14  ................................ ................................ ...............  54 
7.2.8  Cycles 2 -4, Day 28  ................................ ................................ ...............  54 
7.2.9  Cycles 5 -12, Day 1 (Day 29 of prior cycle)  ................................ ........  54 
7.2.10  Cycles 5 -12, Days 2, 3, 4, 5  ................................ ................................ . 55 
7.2.11  Cycles 5 -12, Day 14  ................................ ................................ .............  55 
7.2.12  Cycles 5 -12, Day 28  ................................ ................................ .............  55 
7.3 End of Treatment Visit  ................................ ................................ ...................  56 
7.4 30 Day Safety Follow -up Visit  ................................ ................................ ........  56 
7.5 Long -Term Follow -up................................ ................................ .....................  56 
8.0 STUDY ASSESSMENTS ................................ ................................ ...............  57 
8.1 Safety Assessments  ................................ ................................ .......................  57 
8.1.1  Safety Analysis  ................................ ................................ ....................  57 
8.1.2  Safety  Evaluation  ................................ ................................ ................  57 
8.1.3  Reporting of Adverse Events  ................................ .............................  57 
8.1.4  GVHD Adverse Event Reporting  ................................ ........................  59 
8.2 Efficacy Assessments  ................................ ................................ .....................  61 
8.3 ECGs  ................................ ................................ ................................ .................  62 
8.4 Pharmacokinetics  ................................ ................................ ...........................  62 
8.5 Correlat ives/Exploratory Studies  ................................ ................................ . 63 
8.5.1  Donor/Recipi[INVESTIGATOR_584935]  ................................ ..............................  [ADDRESS_768930] -Transplant Engraftment  ................................ ............................  64 
9.0 STATISTICS  ................................ ................................ ................................  65 
9.1 Safety  ................................ ................................ ................................ ...............  65 
9.2 Sample Size  ................................ ................................ ................................ ..... 65 
9.3 Efficacy Endpo int and Analyses  ................................ ................................ .... 66 
9.3.1  Relapse -Free Survival  ................................ ................................ .........  66 
9.3.2  Overall Survival  ................................ ................................ ...................  66 
1172_CSP 3.0  6 of 81 28 October 2021  
Confidential - Entire Page  9.3.3  Non -Relapse Mortality  ................................ ................................ ....... 66 
9.3.4  Time to Progression (TTP) ................................ ................................ .. 67 
9.3.5  Event -Free Survival (EFS)  ................................ ................................ .... [ADDRESS_768931]/Independent Ethics Committee  ....................  [ADDRESS_768932] of Tables and Figures  
 
Table 1: Dose Modifications for APR -246 ................................ ................................ ........  42 
Table 2: APR-246 Dose Modification in the Setting of Moderate Renal Impairment  42 
Table 3: APR -246-Recommended Dose Modifications and Criteria for Treatment 
Interruption and Re -Initiation for Hepatorenal Toxicities  ................................ ............  44 
Table 4: APR -246 Dose Modifications for Neutropenia with or without Fever  ..........  45 
Table 5: APR -246-Recommended Dose Modifications and Criteria for Treatment 
Interruption and Re -Initiation for Non -Hematological Toxicities  ................................  45 
Table 6. Recommendations for prevention and treatment of cancer -related 
infections  ................................ ................................ ................................ .............................  47 
Table 7: ECG Tim epoints  ................................ ................................ ................................ ... 62 
Table 8: PK Timepoints  ................................ ................................ ................................ ...... 62 
Table  9: Biosampling Timepoints  ................................ ................................ .....................  63 
Table 10: Pre -Screen, APR -246/azacitidine Screening, Cycles 1 -4 (Treatment Period)
 ................................ ................................ ................................ ................................ ..............  76 
Table 11: Cycle 5 -12 (Treatment Period), EOT, 30 day Safety FUV, LTFU  ....................  78 
 
Figure 1: Trial Overview  ................................ ................................ ................................ ..... 31 
Figure 2: Overview of APR -[ADDRESS_768933] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  8 of 81 28 October 2021  
Confidential - Entire Page   
CLINICAL STUDY SYNOPSIS  
Name [CONTACT_790]:   
Aprea Therapeutics AB  Name [CONTACT_122993]:   
 
Title of the Study:    
Phase II trial of APR -246 in combination with azacitidine as maintenance therapy 
for TP53  mutated AML or MDS following allogeneic stem cell transplant  
 
Protocol Number: A19-[ZIP_CODE]  
 
Principal Investigator:  
[INVESTIGATOR_584934] (Moffitt Cancer Center, Tampa FL)  
 
Study Drugs:   APR-246 and azacitidine  
 
Clinical Phase:   II 
 
Objectives:    
Primary Objectives:  
1. To assess relapse -free survival ( RFS) in patients with TP53  mutated AML or 
MDS who receive combination maintenance treatment with APR -246 with 
azacitidine after undergoing allogeneic hematopoietic stem cell transplant 
(HSCT).  
2. To evaluate the safety and tolerability of APR -[ADDRESS_768934].  
 
Secondary Objectives:  
1. To assess the overall survival (OS).  
2. To asses s non-relapse mortality (NRM).  
3. To assess time to progression (TTP).  
4. To evaluate cumulative incidence of Grades II -IV and III -IV acute graft versus 
host diseas e (GVHD).  
5. To evaluate 12 -month cumulative incidence of mild, moderate, and severe 
GVHD.  
6. To describe event -free survival (EFS)  
 
Exploratory Objectives:  
1. To examine the effect of pre - and post -transplant  minimal residual disease  
(MRD ) (TP53  variant allele frequency, VAF) on RFS and overall survival ( OS). 

Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_768935] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_768936] on 
RFS and OS.  
3. To determine if TP53  clonal suppressi on (serial VAF in bone marrow) after 
HSCT correlates with outcomes.  
4. To evaluate APR -246 plasma pharmacokinetics (PK) when administered 
with azacitidine  after transplantation . 
5. To evaluate post -transplant donor engraftment via chimerism studies in 
blood and bone marrow.  
Endpoints:    
Primary Endpoints:  
1. RFS 
2. Incidence, severity, relatedness of adverse events (AEs) and/or laboratory 
abnormalities  
 
Secondary Endpoints:  
1. OS 
2. NRM  
3. Time to progression or relapse  
4. Incidence and grade of acute and chronic GVHD (cumulative)  
5. Incidence and grade of acute and chronic GVHD (1 -year)  
6. EFS 
 
Exploratory Endpoints:  
1. MRD defined by [CONTACT_10216]53  VAF 
2. RFS and OS in relation to baseline p53 protein expression (IHC) and oth er 
potential genomic biomarkers  
3. RFS and OS in relation to clonal suppression, i.e. , depth and duration of TP53  
VAF reduction in bone marrow  samples repeated every 3 months  
4. PK parameters: C max, AUC 0-inf, T1/[ADDRESS_768937] -transplant donor engraftment via chimerism studies in blood and 
bone marrow (whole marrow and CD3/CD33 fractions)  
 
Study Design:    
This is a multi -center, open label, Phase II clinical trial to assess the safety and 
efficacy of APR -[ADDRESS_768938] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_768939] either : 1) pre -
screening next generation sequencing ( NGS ) on peripheral blood (PB) or bone 
marrow (BM) samples at time of HSCT work up to determine presence of TP53  
mutation status or, 2) previously documented evidence of TP53  mutation  by [CONTACT_584959].   
 
Patients will sign consent and be  prescreened for  TP53  mutant AML or MDS before 
they have a HSCT (Day 0).  During the post -HSCT period (Day [ADDRESS_768940]), 
patients are screened for eligibility to receive  APR-246 and azacitidine 
maintenance treatment. In order to proceed with APR -246 and azacitidine 
treatment, neutrophil and platelet engraftment (recovery)  must be confirmed 
between Day [ADDRESS_768941] completed 1 cycle of APR -246 and azacitidine combination 
therapy. The Committee will decide if it is appropriate to continue at the current 
dose; or, in the event the combination is not tolerated the dose of APR -246 will be 
reduced for subsequent patients . 
Trial Overview : 
 
Prescreening (prior to APR -246 and azacitidine)  
 
 
  

Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_768942] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  11 of 81 28 October 2021  
Confidential - Entire Page  APR -246 and Azacitidine Treatment Period, EOT and LTFU  
 
Dose Modification:  
 
 APR-246 Azacitidine  
Starting dose level  3.7g 4h infusion days 1 -4 
q28d cycle  36 mg/m2 sc or iv,  
days  1-5 q28d cycle  
-1 dose level reduction  3.3g 4h infusion days 1 -4 
q28d cycle  36 mg/m2 sc or iv,  
days  1-5 q28d cycle  
-2 dose level reduction  3.0g 4h infusion days 1 -4 
q28d cycle  36 mg/m2 sc or iv,  
days  1-5 q28d cycle  
  
Number of patients:   At least 31 patients  
Inclusion Criteria:   
Pre-Screening :   
These observations will be done ≤ 28 days prior to beginning conditioning 
chemotherapy in anticipation for allograft infusion.  
1. Documentation of a TP53  gene mutation (which is not benign or likely 
benign) by [CONTACT_584960].  
2. Must provide a pre -HSCT bone marrow biopsy.  
3. Age ≥[ADDRESS_768943]/Independent Ethics Committee (IRB/IEC) 
approved written informed consent and privacy language as per national 
regulations (e.g., Health Insurance Portability and Accountability Act 
Authorization (HIPAA) for US sites) obtained fro m the participant or legally 
authorized representative prior to any study -related procedures (including 
withdrawal of prohibited medication, if applicable).   
5. Patient  has confirmed, morphologically documented MDS or AML by [CONTACT_128636].    
6. Patient  is consid ered a suitable candidate for H SCT and has an acceptable 
source of allogeneic donor hematopoietic stem cells, as defined per 

Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_768944] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  12 of 81 28 October 2021  
Confidential - Entire Page  institutional practice (allogeneic HSCT  for any donor source [matched 
sibling, unrelated donor (URD), mismatched URD, related haplo identical,] 
and any graft source [BM, PB], and any non -study conditioning 
[myeloablative conditioning (MAC), reduced intensity conditioning (RIC), or 
non-myeloablative conditioning (NMA)] will be permitted).  Additionally , 
any standard ( non-study) GVHD pro phylaxis regimen will be permitted.  
7. Females must either:  
a. Be of non -childbearing potential  
i. postmenopausal (defined as at least 1 year without menses) 
prior to screening, or  
ii. documented as surgically sterilized at least [ADDRESS_768945] agree not to breastfeed or donate ova  throughout the study 
drug treatment period and for 6 months after the final study drug 
administration.   
9. Males (even if surgically sterilized), and their partners who are women of 
childbearing potential must be using highly effective contraception in 
addi tion to a barrier method throughout the study drug treatment period 
and for [ADDRESS_768946] not donate sperm throughout the study drug treatment period 
and for 127 days after the final study drug administration.  
Exclusion Criteria Pre -Transplant:  
1. Patient has had a prior allogeneic transplant.  
2. Patient has any of the following cardiac abnormalities (as determined by 
[CONTACT_35425] ): 
a. Myocardial infarct within six months prior to registration  
b. [LOCATION_001] Heart Association Class III or IV  heart failure or known left 
ventricular ejection fraction (LVEF) < 40%  
c. A history of familial long QT syndrome  
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_768947] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  13 of 81 28 October 2021  
Confidential - Entire Page  d. Symptomatic atrial or ventricular arrhythmias not controlled by 
[CONTACT_6589]  
e. QTc ≥ 470 ms calculated from a mean of 3 ECG readings using Fridericia’s 
correction (QTcF = QT/RR0.33). Patients with QTc ≥ 470 ms and bundle 
branch block  and/or pacemaker rhythm may be enrolled following  
approval by  [CONTACT_1689] .  
Post-transplant Inclusion Cr iteria  for APR -246 and azacitidine treatment : 
1. Patient has received one allogeneic transplant for AML or MDS.  At time of 
treatment, patient must in morphologic remission for AML or MDS as defined 
as < 5% blasts for AML and ≤ 5% blasts for  MDS,  and in cytogenetic remission 
with no morphologic characteristics of acute leukemia (e.g., Auer Rods) in the 
BM with no evidence of extramedullary disease such as central nervous system 
involvement or granulocytic sarcoma. Patients with CR with incomplete count 
recovery (CRp or CRi) are allowed. Incomplete platelet recovery (CRp) is defined 
as CR with platelet count  < 100 x 109/L. Incomplete blood count recovery (CRi) 
is defined as CR with neutropenia < 1 x 109/L with or without complete platelet 
recovery. Red blo od cell count (RBC) and platelet transfusion independence is 
not required.  
2. Any standard (non -study) conditioning [MAC, RIC, or NMA ] will be permitted. 
Acceptable source of allogeneic donor hematopoietic stem cells, as defined per 
institutional practice (al logeneic HCT for any  donor source [matched sibling, 
URD,  mismatched URD, or related haploidenti cal] and any PB or BM graft 
source.  
3. Patient is ≥ 30 days and ≤ 100 days from hematopoietic cell infusion.  
4. Patient is in complete  remission after the transplant a nd has achieved 
engraftment. Engraftment is defined as ANC≥500/μL and platelets ≥ [ZIP_CODE]/μL 
on 3 consecutive measurements (each occurring at least 1 day apart). The 
patient must not have had a platelet transfusion within [ADDRESS_768948] developed grades II -IV acute GVHD will be allowed to initiate 
maintenance therapy based on the following criteria:  
• Does not require high dose steroids as defined as dosage of > 0.5 mg/kg of 
prednisone (or equivalent) daily dose within [ADDRESS_768949] screening  
• No escalation of systemic immunosuppression in terms of increase of 
corticosteroids or addition of new agent/modality within [ADDRESS_768950] screening.  Dose adjustments (both increase and decrease) of GVHD 
preventative m edications such as calcineurin inhibitors or sirolimus to 
achieve therapeutic trough levels , is allowed. Topi[INVESTIGATOR_584936].   
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_768951] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_768952] either:  
• Be of non -childbearing potential  
o postmenopausal (defined as at least 1 year without menses) prior 
to screening, or  
o documented as surgically sterilized (e.g., hysterectomy or tubal 
ligation) at least 1 month prior to the screening visit  
• Or, if of childbearing potential,  
o Agree not to try to become pregnant during the study and for [ADDRESS_768953] agree not to breastfeed or donate ova throughout the study 
drug treatment period and for 6 months after the final study drug 
administration.  
8. Males (even if surgically sterilized), and their partners who are women of 
childbearing potential must be usi ng highly effective contraception in 
addition to a barrier method throughout the study drug treatment period.  
9. Males must not donate sperm throughout the study drug treatment period.  
10. Agrees not to participate in another interventional study while on 
treatm ent. 
11. Karnofsky Performance Status 70 or greater  is required .  
12. Patient has adequate organ function as defined by [CONTACT_148617]:  
a. Creatinine clearance > 30 mL/min by [CONTACT_3158] -Gault formula;  
b. Total serum bilirubin < 1.[ADDRESS_768954] unless due to Gi lbert's Syndrome, 
underlying disease of MDS, hemolysis or considered an effect of 
regular blood transfusions;  
c. ALT/AST < 2.[ADDRESS_768955] -transplant Exclusion Criteria for APR -246 and azacitidine treatment:  
1. Use of umbilical cord blood donor and stem cell source.  
2. Patient has uncontrolled infection. Definitive therapy for infection is 
required and must have no signs of progression within [ADDRESS_768956] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  15 of 81 28 October 2021  
Confidential - Entire Page  anytime thereafter.   
4. Use of hypomethylating agent, cytotoxic chemotherapeutic agents, or 
experimental agents (agents that are not commercially available) for the 
treat ment of MDS or AML within [ADDRESS_768957] -
transplant. If unsure of the definition of “experimental”, discussion with the 
Medical Mo nitor  is recommended.  
6. Patient requires treatment with supplemental oxygen not including usage 
of non -invasive CPAP  at night.  
7. Patient has any of the following cardiac abnormalities (as determined by 
[CONTACT_35425] ): 
a. Myocardial infarct within six months prior to registration  
b. [LOCATION_001] Heart Association Class III or IV  heart failure or known 
LVEF <40%  
c. A history of familial long Q T syndrome  
d. Symptomatic atrial or ventricular arrhythmias not controlled by 
[CONTACT_6589]  
e. QTc ≥ 470 ms calculated from a mean of 3 ECG readings using Fridericia’s 
correction (QTcF = QT/RR0.33). Patients with  QTc ≥ 470 ms and  bundle 
branch block and/or pacemak er rhythm may be enrolled after approval 
by [CONTACT_1689].  
 
Duration of treatment:    
APR-246 and azacitidine maintenance therapy will continue for a maximum of 12 
cycles or until one of the following criteria applies:  
• Evidence of disease relapse defined as ≥5% blasts for AML patients or >5% 
blasts for MDS patients . Patients who are continu ing to derive clinical 
benefit in the opi[INVESTIGATOR_584937].  
• Inter -current illness that prevents further administration of treatment.  
• Unacceptable adverse event (AE)(s).  
• Patient decides to withdraw from  treatment.  
• General or specific changes in the patient's condition render the patient 
unacceptable for further treatment in the judgment of the investigator.  
• Patient begins other treatment for underlying disease (i.e. , MDS or AML).  
• Grade [ADDRESS_768958] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  16 of 81 28 October 2021  
Confidential - Entire Page   
If the patient discontinues treatment early, then the reason for treatment 
discontinuation and the date the patient was removed will be documented.  
Patients removed from treatment for unacceptable AEs will be followed until 
resolutio n or stabilization of the AE.   
 
Patients may continue to receive study treatment in the setting of relapse or 
progression, up to a maximum of 12 cycles, provided they are continuing to derive 
benefit in the opi[INVESTIGATOR_689].  
Criteria for evaluation:    
Efficacy :  Bone marrow aspi[INVESTIGATOR_584938] 3, cycle 6, cycle 9, and 
cycle 12 , or when clinically indicated , and monthly CBC . 
 
Safety :  CTCAE v5.0. Weekly history and physical for AE assessment (CTCAE v5.0), 
including CBC with diff, CMP and LDH for the first month on treatment, then 
monthly.  
 
GVHD assessment (Harris, 2016 ; Jagasia , 2015 ) will be performed weekly for the 
first month on treatment, then monthly.  
 
PK: Cycle 1 only. Pre -dose, 45 min (+/ - 5min) after SOI, at EOI (4 hr +/ - 30 min after 
SOI), 5 -6 hr after SOI, 24 hr after SOI/Day 2 (before Day 2 dose) . 
 
Statistical M ethods:    
Demographic and clinical variables for the study patients will be summarized 
using descriptive statistics (mean, standard deviation, median, inter -quartile 
range, range, frequency counts and percentages). Safety and efficacy data will be 
analyzed overall as well as separately for each dose cohort when appropriate.  
 
Analysis Populations:  
 
Safety Evaluable Population:  
All subjects who are registered on the study and received any dose of APR -246 or 
azacitidine.  
 
Efficacy Evaluable Population:  
All subjects who are registered on the study and received at least one dose of 
APR-[ADDRESS_768959] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  17 of 81 28 October 2021  
Confidential - Entire Page  relapse/progression.   
 
Sample Size:  
The primary endpoint of the study is the relapse -free survival (RFS) at 12 months. 
The primary analysis will be done using Kaplan -Meier methodology. Based upon 
the published data, the risk of relapse a nd non -relapse mortality in TP53  mutated 
MDS is assumed to be ~40% and ~30% at 1 year, respectively. Thus,  the 
assumptions used for the sample size determination are :  
• the null hypothesis: the RFS at 1 year is 30%,  
• the alternative hypothesis: the RFS at 1 year is 50% or higher,  
• accrual time: 24 months,  
• follow -up time: 12 months,  
• the RFS follows the exponential distribution.  
 
With a one -sided significance level of 10%, 31 subjects will provide 90.1% power to 
test the null hypothesis against the alt ernative. The expected number of events 
during the study is [ADDRESS_768960] is less than or equal to 0.1.  
 
Efficacy Analyses:  
All efficacy analyses will be provided by [CONTACT_584961].  
 
Relapse -Free Survival  
The primary endpoint, RFS, is defined as the time from the date of registration to 
disease relapse after SCT, or death, whichever occurs earlier. If patients 
discontinued treatment due to toxicity, and withdrew consent without relapse 
disease (RD) or death  at the time of data cut off, RFS will be censored at the date 
of the last assessment.  
 
RFS will be analyzed using Kaplan -Meier methodology. Kaplan -Meier curves will be 
plotted. Median relapse -free survival will be estimated and their 95% confidence 
intervals based on Brookmeyer -Crowley methodology will be calculated.  
 
Event -Free Survival  (EFS)  
EFS is defined as from registration to t he first of: morphologic disease relapse, 
death from any cause, reappearance of a pre -transplant cytogenetic  alteration, 
donor lymphocyte infusion ( DLI) for the purpose of treating MDS/AML, or 
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_768961] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  18 of 81 28 October 2021  
Confidential - Entire Page  institution of anti -MDS/AML therapy.  
  
Overall Survival  
Overall survival (OS) is defined as the number of days from the date of registration 
to the date of death, irrespective of the cause. In the event of no death, overall 
survival will be censored at the last known alive date.  
 
OS will be analyzed using the similar methods as RFS. 
 
Non -Relapse Mortality  (NRM)  
NRM is defined as time to deaths without relapse/recurr ence. Deaths from any 
cause without prior progression are events. Events related to the disease such as 
relapse  and progression are competing events . Patients  lost to follow ‐up are 
censored.  
 
NRM will be analyzed  using the similar methods as RFS. 
 
Time to Progression (TTP)  
Time to progression or relapse is time to first event related to the disease, such as 
disease progression, disease relapse/recurrence, death from disease progression, 
and/or initiation of any therapy given to prevent relapse. Deat hs without prior 
relapse/recurrence (i.e. , NRM) are competing events.  
 
TTP will be analyzed using the similar methods as RFS.  
 
Safety  Analyses :  
Safety data including adverse events, vital signs, laboratory data, ECG, physical 
exam will be tabulated for the Safety Evaluable population.  Adverse events will be 
tabulated by [CONTACT_6764], preferred term, severity, and relationship. The 
tabulation of la boratory parameters will include the normal ranges for each 
parameter.  Each value will be classified as falling above, below, or within the 
normal range.  Laboratory parameters will also be tabulated by [CONTACT_584962] -
CTCAE v5 severity grade. Incidence and g rade of acute and chronic GVHD at 1 -year 
and cumulative will be summarized by [CONTACT_6227] ( %) of subjects for each dose level 
and overall.  
 
LIST OF ABBREVIATIONS  
AE adverse events  
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_768962] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_768963] aspartate aminotransferase   
AUC 0-inf area under curve, time 0 to infinity  
BM bone marrow  
CFR Code of Federal Regulations  
Cmax maximum concentration  
CBC complete blood count  
CIBMTR  Center for International Blood and Marrow Transplant Research Repository  
CMP  complete metabolic panel  
CNS central nervous system  
CPAP  continuous positive airways pressure  
CR complete remission  
CRi complete remission with incomplete blood  recovery  
CRp complete remission with incomplete platelet recovery  
CRF case report form  
CTCAE  Common Terminology Criteria for Adverse Events  
DLI donor lymphocyte infusions  
DNA  deoxyribonucleic acid  
ECG electrocardiogram  
EFS event -free survival  
ECOG  Eastern Cooperative Oncology Group (performance status)  
EOI end of infusion  
EOT end of treatment  
ESA erythropoiesis -stimulating agents  
GCP  Good Clinical Practice  
GFR glomerular filtration rate  
GVHD  graft versus host disease  
HCT hematopoietic cell transplant  
HIPAA  Health Insurance Portability and Accountability Act Authorization  
HSCT  hematopoietic stem cell transplant  
IB Investigator's Brochure  
ICH International Council for Harmonisation  
IHC  immunohistochemistry  
IMP investigational medicinal product  
iv intravenous  
IPSS  International Prognosis Scoring System  
IRB/IEC  Institutional Review Board/Independent Ethics Committee  
LDH  lactate dehydrogenase  
LLN lower limit normal  
LTFU  long term follow -up 
LVEF  left ventricular ejection fraction  
MAC  myeloablative conditioning  
MDS  myelodysplastic syndromes  
MRD  minimal residual disease  
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_768964] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_768965] relapse disease  
RFS relapse -free survival  
RIC reduced intensity conditioning  
RP2D  recommended phase II dose  
sc subcutaneous  
SOI start of infusion  
T1/[ADDRESS_768966] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  21 of 81 28 October 2021  
Confidential - Entire Page  1.0 GENERAL INFORMATION  
1.1 Protocol Number and Title of the Study  
A19-[ZIP_CODE]: Phase II trial of APR -[ADDRESS_768967] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  22 of 81 28 October 2021  
Confidential - Entire Page  2.0 BACKGROUND INFORMATION  
2.1 Introduction  
Transplantation of healthy hematopoietic stem cells from an allogeneic donor (HSCT) 
is the only curable treat ment option to improve outcomes for otherwise incurable 
myeloid diseases such as acute myeloid leukemias (AML) and myelodysplastic 
syndromes (MDS). With the development of safer transplant conditioning regimens 
and supportive care measures, transplant can now be offered as a potential curative 
option to a wider population.  However, the potential benefits can be offset by 
[CONTACT_584963].  Disease  recurrence is a major cause 
of treatment failure in patients with AML or MDS who  undergo allogeneic HSCT to 
treat high risk disease, with limited treatment options in the post -HSCT relapsed 
setting.  Thus maintenance strategies need to be explored after transplantation to 
prevent disease recurrence and improve upon survival.  
 
2.2 TP53  Mutations in MDS and AML  
Next generation sequencing (NGS) is becoming more commonly employed as a 
means to provide detailed and rapid assessment of genome studies that continues 
to enhance the diagnostic, prognostic, and therapeutic capabilities within my eloid 
malignancies.[ADDRESS_768968] of the mutation status of TP53 . Not only are (non -benign) TP53  
mutation s associated with decreased OS in mutated patients,4 but also predicts poor 
response and resistance in patients treated with the only currently available FDA -
approved disease modifying agents in MDS, lenalidomide and azacitidine (AZA).4,5,6,7,[ADDRESS_768969] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  23 of 81 28 October 2021  
Confidential - Entire Page  mutant TP53  had similar survival to patients with normal karyotype.11,12  Using the 
Center for International Blood and Marrow Transplant Research Repository 
(CIBMTR), Lindsley and colleagues furthermore reported the largest data analysis to 
date on the prognostic impact genomic mutations in HSCT recipi[INVESTIGATOR_584939].  At 
least 1 g enomic abnormality was detected in nearly 80% of patients who underwent 
HSCT.  TP53  mutations were represented in 19% of all patients and at a higher 
frequency (34%) in patients with Intermediate -2 or High Risk stratification by [CONTACT_584964] (IPSS).  In multivariate analysis, TP53  was 
independently associated with shorter survival and shorter time to relapse in 
comparison to no evidence of TP53  mutation. Three -year overall survival for TP53  
mutated patients was 20% with median overall survival of approximately [ADDRESS_768970]  
Azacitidine (AZA) is a DNA methyltransferase inhibitor that shows significant clinical 
activity in both MDS and AML .13,[ADDRESS_768971] AZA, one year event -free survival 
and overall survival were reported as 58% and 77%, respectively, with reversible 
thrombocytopenia noted to be the dose -limiting toxicity.  Tolerability and efficacy of 
AZA for one year after HCT has been reported by [CONTACT_584965] a l.18  Thirty seven 
patients were treated in AZA in the peri -transplant period with the day 100 and 1 year 
NRM was 0% and 8%, respectively, with no patients having any evidence of chronic 
graft versus host disease, underscoring the tolerability of the treat ment.  The 1 -year 
and 2 -year RFS were 57% and 49%, respectively, with patients demonstrating CD8+ T 
cell response demonstrating reduced relapse rate.  Thus AZA dosing of 36 mg/m2 
subcutaneously for five consecutive days is effective and tolerable, and wi ll be 
utilized at this dose for this study.  
 
 
2.[ADDRESS_768972] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_768973] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_768974] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  26 of 81 28 October 2021  
Confidential - Entire Page   
 
 
 
 
 
 
 
 
 
 
c  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
2.9 Characteristics of a Well -Conducted Trial  
The following character istics of an adequate and well -conducted trial will be 
implemented:  
 
1. The Investigators will be well qualified by [CONTACT_122972].  
 
2. Detailed Case Report Forms (CRFs) will be completed for every patient.  
 

Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_768975] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_768976]/Independent Ethics Committee (IRB/IEC), Title 21 
Code of Federal Regulations (CFR) Part 56, the European Union Directive 
2001/20/EC and its associated Detailed Guidances, Europe an Union GCP 
Directive 2005/28/EC, the ICH Guideline for Good Clinical Practice, Sections 3 
and 4, and the terms of the Declaration of Helsinki ( 2013 ), will be followed.  
 
4. Requirements for informed consent in accordance with institutional 
guidelines, FDA requirements as specified in Title 21 CFR, Part 50, the 
European Union Directive 2001/20/EC and its associated Detailed Guidances, 
European Union GCP Directive 2005/28/EC, the ICH Guideline for Good Clinical 
Practice, Section 4.8, and the terms of the Declaration of Helsinki ( 2013 ), will 
be followed.  
 
5. Safety data will be recorded and evaluated.  
 
6. Routine monitoring visits will be conducted by [CONTACT_1034]’s representative  
( ) to ensure data accuracy.  
 
7. Drug accountability will be strictly maintained.  
 
8. This trial will be conducted according to Good Clinical Practice (GCP), the 
protocol and applicable regulatory requirements.  
 
 
  

Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_768977] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  28 of 81 28 October 2021  
Confidential - Entire Page  3.0 TRIAL OBJECTIVES AND PURPOSE  
3.1 Primary Objectives  
1. To assess relapse -free survival ( RFS) in patients with TP53  mutated AML or 
MDS who receive combination maintenance treatment with APR -[ADDRESS_768978] ant 
(HSCT).  
2. To evaluate the safety and tolerability of APR -[ADDRESS_768979].  
 
3.2 Secondary Objectives  
1. To assess the overall survival (OS).  
2. To asses s non-relapse mortality (NRM).  
3. To assess time to progression  (TTP).  
4. To evaluate cumulative incidence of Grades II -IV and III -IV acute graft versus 
host disease (GVHD).  
5. To evaluate 12 -month cumulative incidence of mild, moderate, and severe 
GVHD.  
6. To describe event -free survival (EFS).  
 
3.[ADDRESS_768980] ( TP53  variant allele 
frequency, VAF) on RFS and OS.  
2. To determine if p53 protein expression and other potential genomic 
biomarkers at baseline before and after HSCT predicts potent ial effect on RFS 
and OS.  
3. To determine if TP53  clonal suppression (serial VAF in bone marrow) after 
HSCT correlates with outcomes.  
4. To evaluate APR -246 plasma pharmacokinetics (PK) when administered with 
azacitidine  after transplantation . 
5. To evaluate post -transplant donor engraftment via chimerism studies in blood  
and bone marrow . 
 
  
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_768981] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  29 of 81 28 October 2021  
Confidential - Entire Page  3.4 Endpoints  
3.4.1  Primary Endpoints  
1. RFS 
2. Incidence, severity, relatedness of adverse events (AEs) and/or laboratory 
abnormalities  
 
3.4.2  Secondary Endpoints  
1. OS 
2. NRM  
3. Time to progression or relapse  
4. Incidence and grade of acute and chronic GVHD (cumulative)  
5. Incidence and grade of acute and chronic GVHD (1 -year)  
6. EFS 
 
3.4.[ADDRESS_768982] defined by [CONTACT_10216]53  VAF 
2. RFS and OS in relation to baseline p53 protein expression (IHC) and oth er 
potential genomic biomarkers  
3. RFS and OS in relation to clonal suppression, i.e. , depth and duration of TP53  
VAF reduction in BM samples repeated every 3 months  
4. PK parameters: C max, AUC 0-inf, T1/[ADDRESS_768983] udies in blood and bone 
marrow (whole marrow and CD3/CD33 fractions)  
 
 
  
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_768984] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_768985] either : 1) pre -
screening NGS on peripheral blood (PB) or bone marrow (BM) samples at time of 
HSCT work up to determine presence of TP53  mutation status or, 2) previously 
documented evidenc e of TP53  mutation by [CONTACT_584966].   
 
Patients will sign consent and be prescreened for TP53  mutant AML or MDS before 
they have a HSCT (Day 0). During the post -HSCT period (Day [ADDRESS_768986]), 
patients are screened for eligibility to recei ve APR -246 and azacitidine maintenance 
treatment. In order to proceed with APR -246 and azacitidine treatment, neutrophil 
and platelet engraftment (recovery) must be confirmed between Day [ADDRESS_768987] 6 patients ha ve completed 1 cycle of APR -246 and azacitidine combination 
therapy. The Committee will decide if it is appropriate to continue at the current 
dose; or, in the event the combination is not tolerated  (e.g. patients experience dose 
limiting toxicity) the dos e of APR -[ADDRESS_768988] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  31 of 81 28 October 2021  
Confidential - Entire Page   
Figure 1: Trial Overview  
 
Enrollment, Pre -screening, Pre -/Post -HSCT APR -[ADDRESS_768989] completed 1 cycle of APR -246 and azacitidine combination 
therapy. If >1 of 6 patients experience any of the following toxicities , then the 
APR-246 dose  will be reduced for subsequent ly enrolled patients .  
 
• Treatment related non -hematological CTCAE grade 3 -4 toxicity that lead to 
dose modification or withdrawal.  
• Absolute neutrophil count (ANC) not recovering to >500/μL by [CONTACT_4475] 56 of a cycle 
in the absence of active leukemia/myelodysplasia.  
• Grade 3 metabolic/electrolyte abnormalities that are clinically significant, and 
not adequately controlled within [ADDRESS_768990] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  32 of 81 28 October 2021  
Confidential - Entire Page  • Grade 3 nausea/vomiting/diarrhea or CNS toxicity that does not resolve within 
28 days despi[INVESTIGATOR_550580].  
 
4.3 Study Stoppi[INVESTIGATOR_524667], the study will be temporarily paused until a full review  
by [CONTACT_584967]:  
• Any death (other than death related to progressive disease) that occurs within 
[ADDRESS_768991] patient 
undergoing the trial. 
 
4.5 Duration of Therapy  
Maintenance therapy will continue for a maximum of 12 cycles (28 day s/cycle) from 
first dose of APR -246, or until one of the follow ing criteria applies:  
• Evidence of disease relapse defined as ≥5% blasts for AML patients or >5% 
blasts for MDS patients . Patients who are continuing to derive clinical benefit 
in the opi[INVESTIGATOR_584940].  
• Inter -current illness that prevents further administration of treatment.  
• Unacceptable AEs.  
• Participant decides to wi thdraw from treatment.  
• General or specific changes in the patient's condition render the patient. 
unacceptable for further treatment in the judgment of the investigator.  
• Participant begins other treatment for underlying disease (MDS or AML).  
• Grade [ADDRESS_768992] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  33 of 81 28 October 2021  
Confidential - Entire Page  Patients may continue to receive study treatment in the setting of relapse or 
progression, up to a maximum of 12 cycles, provided they are continuing to derive 
benefit in the opi[INVESTIGATOR_689].  
 
4.6 Trial Discontinuation  
For reasonable cause, either the Investigator or the Sponsor may terminate this 
study premature ly. Written notification of the termination is required.  Conditions 
that may warrant termination include, but are not limited to:  
 
• The discovery of an unexpected, significant, or unacceptable risk to the patients 
enrolled in the study.  
• Failure of the Inve stigator to enter patients at an acceptable rate.  
• Insufficient adherence to protocol requirements (non -compliance).  
• Lack of evaluable and/or complete data.  
• Decision to modify the developmental plan of the drug.  
• A decision on the part of the Sponsor to susp end or discontinue development of 
the drug.  
 
4.7 Drug Accountability/Disposition of Clinical Trial Supplies  
Drug accountability records will be maintained for all clinical trial supplies.  
 
All unused clinical trial supplies will be returned to the Sponsor, or at the Sponsor's 
directive, destroyed by [CONTACT_584968].  
 
4.[ADDRESS_768993] meet all eligibility requirements listed in 
Section  5.0.  Patients will be registered  on the study by [CONTACT_550626] (IWRS) automated patient registration system  (see 
the Study Operations Manual for specific instructions).  
 
  

Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_768994] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_768995] meet:  
• Transplant and enrollment criteria in Section s 5.1.1 -5.1.2 ; and , 
• APR-246 and azacitidine treatment criteria  in Section s 5.2.1 -5.2.2 . 
 
5.1 Pre-Screening  
5.1.1  Inclusion Criteria  
These observations will be done ≤ 28 days prior to beginning conditioning 
chemotherapy in anticipation for allograft infusion.  
 
1. Documentation of a TP53  gene mu tation (which is not benign or likely benign) 
by [CONTACT_584969].  
2. Must provide a pre -HSCT bone marrow biopsy.  
3. Age ≥[ADDRESS_768996] /Independent Ethics Committee (IRB/IEC) approved 
written informed consent and privacy language as per national regulations 
(e.g., Health Insurance Portability and Accountability Act Authorization (HIPAA) 
for US sites) obtained from the participant or legal ly authorized representative 
prior to any study -related procedures (including withdrawal of prohibited 
medication, if applicable).   
5. Patient has confirmed, morphologically documented MDS or AML by [CONTACT_128636].      
6. Patient is considered a suitable candidate for HSCT and has an acceptable 
source of allogeneic donor hematopoietic stem cells, as defined per 
institutional practice (allogeneic HSCT for any donor source [matched sibling, 
unrelated donor (URD), mismatched U RD, related haploidentical] and any graft 
source [BM, PB], and any non -study conditioning [myeloablative conditioning 
(MAC), reduced intensity conditioning (RIC), or non -myeloablative conditioning 
(NMA)] will be permitted).  Additionally, any standard (non -study) GVHD 
prophylaxis regimen will be permitted.  
7. Females must either:  
a. Be of non -childbearing potential  
i. postmenopausal (defined as at least 1 year without menses) prior 
to screening, or  
ii. docum ented as surgically sterilized at least [ADDRESS_768997] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_768998] agree not to breastfeed or donate ova throughout the study 
drug treatment period and for 6 months after the final study drug 
adm inistration.   
9. Males (even if surgically sterilized), and their partners who are women of 
childbearing potential must be using highly effective contraception in addition 
to a barrier method throughout the study drug treatment period and for [ADDRESS_768999] not donate sperm throughout the study drug treatment period 
and for 127 days after the final study drug administration.  
 
5.1.2  Exclusion Criteria  
1. Patient has had a prior allogeneic transplant.  
2. Patient has any of t he following cardiac abnormalities (as determined by 
[CONTACT_35425] ): 
a. Myocardial infarct within six months prior to registration  
b. [LOCATION_001] Heart Association Class III or IV  heart failure or known left 
ventricular ejection fraction (LVEF) < 40%   
c. A history of familial long QT syndrome  
d. Symptomatic atrial or ventricular arrhythmias not controlled by 
[CONTACT_6589]  
e. QTc ≥ 470 ms calculated from a mean of 3 ECG readings using Frideric ia’s 
correction (QTcF = QT/RR0.33). Patients with QTc ≥ 470 ms and bundle 
branch block and/or pacemaker rhythm may be enrolled after approval by 
[CONTACT_25290].  
5.[ADDRESS_769000] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_769001] in  morphologic  remission for AML or MDS as defined as 
< 5% blasts  for AML and ≤ 5% blasts for MDS,  and in cytogenetic remission with 
no morphologic character istics of acute leukemia (e.g., Auer Rods) in the BM with 
no evidence of extramedullary disease such as central nervous system 
involvement or granulocytic sarcoma. Patients with CR  with incomplete count 
recovery (CRp or CRi) are allowed. Incomplete platele t recovery (CRp) is defined 
as CR with platelet count  < 100 x 109/L. Incomplete blood count recovery (CRi) is 
defined as CR with neutropenia < 1 x 109/L with or without complete platelet 
recovery. Red blood cell count (RBC) and platelet transfusion indepen dence is not 
required.  
2. Any standard (non -study) conditioning [MAC, RIC, or NMA] will be permitted. 
Acceptable source of allogeneic donor hematopoietic stem cells, as defined per 
institutional practice (allogeneic HCT for any donor source [matched sibling, URD, 
mismatched URD, related haploidentical] and any graft source [BM, PB].  
3. Patient is ≥ 30 days and ≤ 100 days from hematopoietic cell infusion.  
4. Patient is in complete remission after the transplant and has achieved 
engraftment. Engraftment is defined as  ANC≥500/μL and platelets ≥ [ZIP_CODE]/μL on 
3 consecutive measurements (each occurring at least 1 day apart). The patient 
must not have had a platelet transfusion within [ADDRESS_769002] developed grades II -IV acute GVHD  will be allowed to initiate 
maintenance therapy based on the following criteria:  
• Does not require high dose steroids as defined as dosage of > 0.5 mg/kg of 
prednisone (or equivalent) daily dose within [ADDRESS_769003] screening  
• No escalation of systemi c immunosuppression in terms of increase of 
corticosteroids or addition of new agent/modality within [ADDRESS_769004] 
screening.  Dose adjustments (both increase and decrease) of GVHD 
preventative medications such as calcineurin inhibitors or sirolimus  to achieve 
therapeutic trough levels, is allowed. Topi[INVESTIGATOR_584941].   
6. Females must either:  
• Be of non -childbearing potential  
o postmenopausal (defined as at least 1 year without menses) prior to 
screening, or  
o documented as surgically sterilized (e.g., hysterectomy or tubal 
ligation) at least 1 month prior to the screening visit  
• Or, if of childbearing potential,  
o Agree not to try to become pregnant during the study and for [ADDRESS_769005] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_769006] agree not to breastfeed or donate ova throughout the study drug 
treatment period and for 6 months after the final study drug administration.  
8. Males (even if surgically s terilized), and their partners who are women of 
childbearing potential must be using highly effective contraception in addition to 
a barrier method throughout the study drug treatment period.  
9. Males must not donate sperm throughout the study drug treatment  period.  
10. Agrees not to participate in another interventional study while on treatment.  
11. Karnofsky Performance Status 70 or greater  is required. ( APPENDIX  A)  
12. Patient has adequate organ function as defined by [CONTACT_148617]:  
a. Creatinine clearance > 30 mL/min by [CONTACT_3158] -Gault formula;  
b. Total serum bilirubin < 1.[ADDRESS_769007] unless due to Gilbert's Syndrome, 
underlying disease of MDS, hemolysis or considered an effect of regular 
blood transfusions;  
c. ALT/AST < 2.[ADDRESS_769008] screening or anytime 
thereaft er.  
4. Use of hypomethylating agent, cytotoxic chemotherapeutic agents, or 
experimental agents (agents that are not commercially available) for the 
treatment of MDS  or AML within [ADDRESS_769009] -
transplant. If unsure of the definition of “experimental”, discussion with the 
Medical Monitor  is recommended.  
6. Patient requires treatment with supplemental oxygen not including usage of 
non-invasive CPAP at night.  
7. Patient has any of the following cardiac abnormalities (as determined by 
[CONTACT_584970] s, Inc.  
Protocol Number A19 -[ADDRESS_769010] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  38 of 81 28 October 2021  
Confidential - Entire Page  treating physician ): 
a. Myocardial infarct within six months prior to registration  
b. [LOCATION_001] Heart Association Class III or IV  heart failure or known LVEF<  40%  
c. A history of familial long QT syndrome  
d. Symptomatic atrial or ventricular arrhythmias not controlled by 
[CONTACT_6589]  
e. QTc ≥ 470 ms calculated from a mean of 3 ECG readings using Fridericia’s 
correction (QTcF = QT/RR0.33). Patients with QTc ≥ 470 ms and  bundle 
branch block and/or pacemaker rhythm may be enrolled after approval by 
[CONTACT_25290].  
5.3 Withdrawal Criteria  
Protocol therapy will be discontinued at any time if any of the following situations 
occur:  
 
1. Relapsed disease , unless Investigator believes patient is receiving clinical benefit .  
2. The development of toxicity which, in the Investigator’s judgme nt, precludes 
further therapy.  
3. Patie nt refusal.  
4. Lost to follow -up/noncompliance.  
5. Intercurrent illness.  
6. At the discretion of the Investigator.  
7. Pregnancy.  
8. Study termination.  
9. Initiation of anti -MDS/AML therapy or DLI for purpose of treating MDS/AML.  
 
5.3.[ADDRESS_769011] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  39 of 81 28 October 2021  
Confidential - Entire Page  6.0 TREATMENT OF SUBJECTS  
6.1 Drug Preparation and Administration  
Patients will receive APR -246 and azacitidine on days 1-4 and 1 -5, respectively, every 
28-day cycle . APR-246 and azacitidine are administered in the clinic.  
 
Figure  2: Overview of APR -246 and Azacitidine  Treatment  Per Cycle  
APR -246 
administration  → → → →   Next Cycle:  
Day 1 2 3 4 5 6-28 D29 prior cycle/D1  
Azacitidine 
administration  
→ 
→ 
→ 
→ 
→  +4 wk window 
permitted  
 
6.1.1  APR -246 
At the pharmacies, the IMP vials are to be stored at 2 -8ºC (35.6 -46.4F). At the 
pharmacies and at the study centers, the prepared APR -[ADDRESS_769012] (diluted 
in sodium chloride solution) is to be stored at not more than 25ºC. The infusion 
should be completed within 24 hours from the time of preparation (see Study 
Manual) .  
 
A fixed dose of 3.7g APR -246 will be administered as an intravenous infusion daily on 
days 1 -4 of each 28  day cycle. Total infusion time is 4 hours, administered in 2 
consecutive steps:  
1)  1.[ADDRESS_769013] 45 minutes (+/ - 2 min)  
2) 2.1 g over 3 hours 15 minutes (+/ - 15 min)  
 
Detailed instructions on vial concentration, preparation and dispensing can be found 
in the Pharmacy Manual. The infusion timing, including start/stop times and the time  
of rate change, must be recorded.  
 
6.1.2  Azacitidine  
Azacitidine (36 mg/m2) is administered sc or iv  for [ADDRESS_769014] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  40 of 81 28 October 2021  
Confidential - Entire Page  6.2 Criteria for Retreatment and Dose Modifications  
This section outlines the requirements for proceeding with treatment with APR -246, 
and the protocol rules for APR -246 dose modification due to toxicity.  
 
ECGs  
For all patients  
• Patients with screening QTcF ≥470 ms (average from triplicate ECG) are 
excluded from the study. Rescreening is allowed.  
• At a minimum, ECG should be performed pre -dose and end -of-infusion (EOI) 
on Day 1, Cycle 1 -4. This ECG may be done as single or replicate (i.e. duplicate 
or triplicate, average QTcF should be used). Patients with screening or any pre -
dose 450 ≤ QTc < [ADDRESS_769015] to more intense ECG monitoring 
(see below).  
• If a pre -dose ECG shows QTcF ≥470 ms the QTc reading should be manually 
confirmed. Serum concentrations of electrolytes should be controlled and 
adjusted if necessary. Concomitant medication s hould be reviewed and 
adjusted if necessary. A new ECG may be done at any time, even the same day. 
The patient should not be treated unless QTc is <470. If the dose is given later 
on the same day, follow the planned cycle. If the dose cannot be given, omit  
that dose from the cycle.  
• If the patient at any time during the study starts with a concomitant 
medication known to prolong the QT interval, a pre -dose and EOI ECG should 
be performed for the next planned dose  
• If any ECG during the study shows a significa nt change (vs baseline or pre -
dose) in QTcF, defined as either i) increase >60 ms, ii) increase >25 %, or iii) 
increase to an absolute value ≥500 ms, the dose should be held/interrupted. 
If the QTc prolongation is confirmed by a manual read, the therapy sh ould 
stop until the cause has been identified and eliminated (electrolyte 
disturbance or concomitant drug) and QTc is again <470ms. Discontinue APR -
246 permanently, if other causes for clinically significant QTcF increase are 
excluded . 
 
Additional monitori ng for patients with 450 ≤ QTc < 470 ms at baseline or any 
pre-dose measurement  
• ECG should be performed pre -dose and end -of-infusion (EOI) for all doses (Day 
1-4, all cycles). This ECG may be done as single or replicate (i.e. , duplicate or 
triplicate, aver age QTcF should be used).  
• Dose should be held for pre -dose QTcF ≥470 ms (see above). For a post -dose 
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769016] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  41 of 81 28 October 2021  
Confidential - Entire Page  (EOI) ECG showing >60 ms increase vs pre -dose or any QTcF >500 ms, see 
above.  
• Patients should avoid QTc prolonging drugs on infusion days, if possible, an d 
have any electrolyte imbalance checked and corrected (CTCAE ≤Grade 1).  
• If repeated QTcF measurements show a stable QTcF <450, or if the patient is 
stable in the interval 450 to <470 ms with no significant change at EOI (several 
cycles of treatment) the i nvestigator may discuss with the Medical Monitor to 
decrease the number of ECGs performed in the study.  
 
Other toxicity  
All dose modifications, interruptions or discontinuations must be based on the worst 
preceding toxicity as graded by [CONTACT_584971] (NCI -CTCAE version 
5). Once a dose has been reduced during a treatment cycle, re -escalation will not be 
permitted during any subsequent cycle (with exception of CNS events). If the 
administration of APR -246 is interrupted for rea sons other than toxicity, then 
treatment with APR -246 may be resumed at the same dose. The same provision 
applies if the patient experienced an unacceptable toxicity not specifically described 
in this section, provided that this toxicity resolved to ≤ CTCA E grade 1, unless 
otherwise specified.  
 
Day 1 of next cycle treatment with APR -246 and azacitidine can be delayed for up to 
4 weeks (28 days) to allow for count recovery at Investigator discretion pending 
discussion with the Sponsor and Medical Monitor. No n-hematologic grade 4 
treatment related adverse events will lead to permanent discontinuation, 
irrespective of recovery time, unless otherwise specified.  
 
Exceptions would include nausea/vomiting/diarrhea which can be controlled by 
[CONTACT_584972]/or asym ptomatic electrolyte imbalances which can be corrected. In 
addition, in most instances, patients that experience a prolonged treatment 
interruption because of an adverse event and/or a grade 3 adverse event will 
decrease the dose of study drug after their recovery  (see tables in this section for 
dose adjustment guidelin es).  
 
If any other drug -related grade [ADDRESS_769017] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  42 of 81 28 October 2021  
Confidential - Entire Page  6.2.1  Dose Modifications  
Table 1: Dose Modifications for APR -246  
 APR-246 Azacitidine  
Starting dose level  3.7g 4h infusion days 1 -4 
q28d cycle  36 mg/m2 sc or iv,  
days  1-5 q28d cycle  
-1 dose level reduction  3.3g 4h infusion days 1 -4 
q28d cycle  36 mg/m2 sc or iv,  
days  1-5 q28d cycle  
-2 dose level reduction  3.0g 4h infusion days 1 -4 
q28d cycle  36 mg/m2 sc or iv,  
days  1-5 q28d cycle  
 
 
APR-246 is partially eliminated via the kidney and moderate renal impairment, 
defined by a creatinine clearance, or estimated glomerular filtration rate value of >30 
to <60 mL/min, can lead to increases in plasma levels of approximately 30%. 
Therefore, for patients with moderate renal impairment, the dose of APR -246 should 
be reduced by 33% from the curren t dose ( Table 2). 
 
Table 2: APR -246 Dose Modification in the Setting of Moderate Renal Impairment  
APR -246 Dose  33% Reduced Dose  Loading Dose (over 
45 min)  Maintenance Dose 
(over 3 hr and 15 
min)  
3.7 g 2.5 g 1.1 g 1.4 g 
3.3 g 2.2 g 1.0 g 1.2 g 
3.0 g  2.0 g  0.9 g 1.1 g 
<3.0 g  Please consult with Medical Monitor  
 
Monitoring renal function by [CONTACT_584973]-246 is recommended in all patients.  
 
Patients requiring >[ADDRESS_769018] follow -up within 30 days after discontinuation of all study treatment or 
resolution of the AE to ≤  grade 1, whichever occurs first, that includes all study 
assessments appropriate to monitor the event.  
 
Azacitidine dose modif ications will be per the prescribing information and 
institutional guidelines.  Patients may continue with APR -246 without azacitidine if ≥ 
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769019] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_769020] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  44 of 81 28 October 2021  
Confidential - Entire Page  Table  3: APR -246-Recommended Dose Modifications and Criteria for 
Treatment Interruption and Re -Initiation for Hepatorenal Toxicities  
Hepatorenal Toxicities  
Worst toxicity (CTCAE 5 Grade)† Dose Modifications for APR -246 
Serum  Creatinine  
Grade 1 (< 1.5 × ULN)  Maintain dose level  
Grade 2 (> 1.5 to 3.0 × ULN)  Omit dose until resolved to ≤ Grade 1, then:  
If resolved in ≤ 7 days, then maintain dose level  
If resolved in > 7 days, then  1 dose level  
Grade 3 (> 3.0 – 6.0 × ULN)  If resolved in ≤ 7 days, then  1 dose level  
If resolved in > 7 days, discontinue patient from APR -246  
Grade 4 (> 6.0 × ULN)  Permanently discontinue patient from APR -246 
Bilirubin‡  
Grade 1 (> ULN - 1.5 × ULN)  Maintain dose level with LFTs* monitored as per protocol  
Grade 2 (> 1.5 - 3.0 × ULN) with ALT or 
AST ≤ 3.0 × ULN  Omit dose until resolved to ≤ Grade 1, then:  
If resolved in ≤ 7 days, then maintain dose level  
If resolved in > 7 days, then  1 dose level  
Grade 3 (> 3.0 - 10.0 × ULN) with ALT or 
AST ≤ 3.0 × ULN  Omit dose until resolved to ≤ Grade 1, then:  
If resolved in ≤ 7 days,  1 dose level  
If resolved in  7 days, discontinue patient from APR -246 
Grade 4 (> 10.0 × ULN)  Permanently discontinue patient from APR -[ADDRESS_769021] or ALT  
Grade 1 (> ULN - 3.0 × ULN if baseline 
was normal; 1.5 - 3.0 × baseline if 
baseline was abnormal)  Maintain dose level with LFTs* monitored per protocol  
Grade 2 (> 3.0 - 5.0 × ULN if baseline 
was normal; >3.0 - 5.0 × baseline if 
baseline was abnormal) without total 
bilirubin elevation to > 2.0 × ULN  Omit dose until resolved to ≤ Grade 1, then  
If resolved in ≤ 7 days, then maintain dose level  
If resolved in > 7 days, then  1 dose le vel 
Grade 3 (> 5.0 - 20.0 × ULN if baseline 
was normal; > 5.0 – 20.0 x baseline if 
baseline was abnormal) without total 
bilirubin elevation to > 2.0 × ULN  Omit dose until resolved to ≤ Grade 1, then  
If resolved in ≤ 7 days, then maintain dose level  
If resolved in > 7 days, then  1 dose level  
Grade 4 (> 20.0 × ULN if baseline was 
normal; > 20.0 × baseline if baseline was 
abnormal) without bilirubin elevation to 
> 2.0 × ULN  Permanently discontinue patient from APR -246 
*(LFTs include albumin, ALT, AST, total bilirubin (fractionated if total bilirubin > 2.0 × ULN), alkaline 
phosphatase.  
† Common Terminology Criteria for Adverse Events (CTCAE) version 5.  
‡ For patients with Gilbert’s syndrome, these dose modifications apply to changes in direct bilirubin only.  
* LFTs include albumin, ALT, AST, total bilirubin (fractionated if total bilirubin > 2.0 × ULN), alkaline phosphatase.  
 
 
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769022] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  45 of 81 28 October 2021  
Confidential - Entire Page  Table 4: APR -246 Dose Modifications for Neutropenia with or without Fever  
Parameter † Worst toxicity ‡ Dose modifications for APR -[ADDRESS_769023] 
occurrence  • Interrupt dosing and monitor patient; 
treat promptly.  
• Resume at current dose level if 
neutropenia and fever (if present) 
resolve to baseline within 7 days after 
onset.  
• If toxicity does not resolve to baseline 
despi[INVESTIGATOR_241786](s) 
within  7 days of onset, then reduce APR -
246 by 1 dose level once the toxicity 
resolves to baseline.  
• Initiate or reassess prophylaxis 
measures. Refer to Sections 6.3.3  and 
6.3.4  for supportive management 
guidelines specific to infection 
prophylaxis and neutropenia, 
respectively.  
 2nd occurrence  • Hold all study treatments and monitor 
patient; treat promptly.  
• Assess current infection prophylaxis 
and adjust treatment plan as clinically 
indicated. Refer to Sections 6.3.3  and 
6.3.4  for supportive management 
guidelines specific to infection 
prophylaxis and neutropenia, 
respectively.  
• While APR -246 and azacitidine are 
interrupted, consult with study medical 
monitor to determine if a dose 
modification of APR -246 is warranted.   
Thrombocytope
nia Grade 4 (platelet 
count <25 x 
109/L) and major 
bleeding event  Permanently discontinue patien t from APR -246.  
† Only applicable for patients with normal baseline absolute neutrophil count (ANC) and platelets)  
‡ Common Terminology Criteria for Adverse Events (CTCAE) version 5.  
 
 
Table 5: APR -246-Recommended Dose Modifications and Criteria for 
Treatment Interruption and Re -Initiation for Non -Hematological Toxicities  
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769024] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_769025] toxicity 
(CTCAE 5 Grade)† Dose Modifications for APR -246 
CNS – dizziness, dyskinesia and ataxia  
Grade 1  Maintain dose level  
Grade 2  If resolved with medical therapy, continue same dose level  
If not resolved despi[INVESTIGATOR_427670], 
stop infusion and  1 dose level for subsequent dose  
Grade 3  If resolved with medical therapy, continue same dose level  
If not resolved despi[INVESTIGATOR_427670], 
stop infusion and  1 dose level for subsequent dose  
Grade 4  Permanently discontinue patient from APR -246.  
Infusion Related Reaction  
Grade 1  Maintain dose level.  
Grade 2  Maintain dose level; Symptomatic management (e.g., antihistamines, 
corticosteroids, narcotics, IV fluids)  
Grade 3  If resolved in < 4 hours with treatment interruption and medical therapy (e.g., 
antihistamines, corticosteroids, narcotics, IV fluids), continue same dose level 
and rate.  
If not resolved in < 4 hours despi[INVESTIGATOR_584942], stop infusion and  1 dose level for subsequent dose  
Grade 4  Permanently discontinue patient from APR -246.  
Nausea/Vomiting/Diarrhea  
Grade 1  Maintain dose level  
Grade 2  If resolved, then maintain dose level  
If not resolved despi[INVESTIGATOR_133349],  
then  1 dose level  
Grade 3  If resolved, then maintain dose level  
If not resolved despi[INVESTIGATOR_133349], then  1 dose level  
Grade 4  Permanently discontinue patient from APR -246 
Any Other Toxicity   
Grade 3 or 4  Delay dose until resolution to ≤ Grade1, then  1 dose level  
† Common Terminology Criteria for Adverse Events (CTCAE) version 5.  
 
6.[ADDRESS_769026] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  47 of 81 28 October 2021  
Confidential - Entire Page   
[IP_ADDRESS]  Management of Acute GVHD  
Acute GVHD should be managed per institutional guidelines. Therapi[INVESTIGATOR_584943].  
 
[IP_ADDRESS]  Management of Chronic GVHD  
Chronic GVHD should be managed per institutional guidelines. Therapi[INVESTIGATOR_584944] y while on treatment is not 
allowed.  
 
 
 
 
 
 
 
 
As  
 
 
 
 
 
  
 
The following re commendations were taken from National Comprehensive Cancer 
Network Guidelines for Prevention and Treatment of Cancer -Related Infections 
(Version 1.2021).  
 
Table 6. Recommendations for prevention and treatment of cancer -related 
infections  
Organism  Recommendations  
Bacterial  Consider fluoroquinolone or other suitable anti -bacterial prophylaxis during 
neutropenia  

Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769027] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_769028] agent(s) as 
clinically indicated.   
Viral  Start treatment with anti -viral medication in the setting of neutropenia and 
conti nually assess the risk for viral infection during treatment with anti -cancer 
therapy.  
  
Refer to Section 6.2 for guidance on APR -246 dose modification  in the setting severe 
infection and/or infestation event, using the parameter titled, “Any Other Toxicity” 
(Table 5). 
   
Refer to Section 6.[ADDRESS_769029] ete blood counts at the time of study enrollment and throughout the 
course of study treatment. Supportive measures such as antimicrobials for 
prophylaxis or in the setting of prolonged myelosuppression, and/or at the first signs 
of infection are recommende d to reduce the risk of a serious or severe infection that 
may lead to a fatal outcome in the setting of neutropenia with or without fever (see 
Section 6.3.3 ). 
 
Myeloid growth factors may be used in the setting of severe or prolonged 
neutropenia. Refer to Section 6.3 for a description of drugs that are not allowed to 
be used while a patient is on study treatment.  
 
Refer  to Section 6.2.1  for APR -246 dose modification in the setting of severe or life -
threatening neutropenia with or without fever.  
 
 
6.3.5  General Concomitant Medications and Supportive Care Guidelines  
[IP_ADDRESS]  Antimicrobials  
Antibacterial, antiviral and antifungal prophylaxis and treatment during and after 
allogeneic HSCT are recommended and can be administered based on local 
institutional guidelines.  
 
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769030] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  49 of 81 28 October 2021  
Confidential - Entire Page  [IP_ADDRESS]  Tapering of GVHD Prophylaxis  
Tapering of immunosuppression should be followed per institut ional practice in the 
absence of GVHD. There are no formal recommendations given that participants 
receiving HCT from any type of donor, after any conditioning and receiving any GVHD 
prophylaxis regimen are eligible.  
 
[IP_ADDRESS]  Donor Lymphocyte Infusions  
Pre-emptive /prophylactic administration of donor lymphocytes for disease 
progression (morphological or molecular) is not permitted in this protocol. DLI for 
infectious complications or modulation of T cell donor chimerism after allograft 
administration per institutio nal guidelines is allowed. For any unresolved questions 
regarding DLI administration should be discussed with the Medical Monitor . 
 
6.3.6  Prohibited Therapy  
• Other anticancer therapy:  Anticancer therapy (chemotherapy, endocrine, 
biologic or radiation therapy, an d surgery) other than the study treatments 
must not be given to patients while the patient is enrolled in the treatment 
portion of the trial. If such agents are required for a patient then, the patient 
must be permanently discontinued from the treatment po rtion of the study. 
Exception: for breast cancer or prostate patients on adjuvant hormonal 
therapy (e.g., anastrozole/tamoxifen or leuprolide) who have been disease 
free for at least 1 year.  
 
• Other investigational therapi[INVESTIGATOR_014]: Other investigational therapi[INVESTIGATOR_584945].  
 
6.3.7  Other Concomitant Treatment (Medication and Non -medication 
Therapy)  
In general, the use of any concomitant medications/therapi[INVESTIGATOR_214758], with specific exceptions below. Prophylactic anti -
emetic therapy is permitted where indicated.  Participating centers will adhere to 
institutional practice regarding the monitoring of serum levels of 
immunosuppressive agents such as ta crolimus or azoles.   
 
Any disease progression that requires other specific anti -tumor therapy will be cause 
for discontinuation from the trial.  
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769031] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  50 of 81 28 October 2021  
Confidential - Entire Page   
6.3.8  Permitted Medications  
[IP_ADDRESS]  Growth Factors  
Erythropoiesis -stimulating agents (ESAs) are not allowed for anemia during the 
study. G-CSF is allowed for evidence of neutropenia.  
 
[IP_ADDRESS]  Anticoagulant Therapy  
Subjects who are taking warfarin (or equivalent) may participate in this study; 
however, it is recomm ended that prothrombin time (PT -INR) and PTT be monitored 
carefully at least once per week for the first month, then monthly if the INR is stable. 
Subcutaneous heparin, low molecular weight heparin and oral anticoagulants are 
permitted.  
 
[IP_ADDRESS]  Blood Products  
The use of blood products to include packed red blood cells (PRBCs) and platelet 
transfusions are permitted and to be given at the discretion of the treating physician. 
Recommended guidelines for transfusion include a platelet threshold of 10,000/L for 
platel et transfusion and a hemoglobin threshold of 8.0g/dL for PRBC transfusion or 
as clinically deemed by [CONTACT_584974].  
 
6.[ADDRESS_769032] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  51 of 81 28 October 2021  
Confidential - Entire Page  7.0 STUDY EVALUATIONS  
Unscheduled visits and laboratory monitoring may occur as needed. Window of 3 
days applies except where noted.  
 
7.1 Pre-Screening  
APPENDIX B lists visits and assessments  prior to starting APR -246 and azacitidine . 
Unscheduled visits and laboratory monitoring may occur as needed.  
 
7.1.1  Pre-Screening ( Day -[ADDRESS_769033] ) 
• Sign informed consent  
• TP53  mutation confirmation  
• Disease assessment : BM aspi[INVESTIGATOR_6706]/or biopsy sample must be collected  
prior to the start of the pre -transplant conditioning regimen .  
• Pregnancy test (women of child -bearing potential only)  
• ECGs; see Table 7.  
 
7.1.2  Day 0  
• Transplant  
 
7.1.[ADDRESS_769034] -Transplant, APR -246 Screening  Period  (Day 1 to 100)  
Post -HSCT evaluation  will occur as per institutional standard practices.  
 
APR-246/azacitidine screening  period occu rs during Day [ADDRESS_769035]. The 
date will vary but should start (Day -[ADDRESS_769036] dose) as soon as engraftment 
and the requirements in Section 7.1.[ADDRESS_769037] 
dose, or as indicated.  Starred (*) procedures should be done within [ADDRESS_769038] dose.  
 
• Sign informed consent  
• Disease assessment  
• Eligibility  
• Karnofsky performance status  
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769039] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  52 of 81 28 October 2021  
Confidential - Entire Page  • Medical history and Transplant Details  
• Physical exam with Weight*  
• Vital signs * 
• CBC*  
• CMP*  
• ECGs *; see Table 7.  
• Pregnancy test (women of child -bearing potential only)*  
• Pre-treatment/baseline Bone marrow (BM)/Aspi[INVESTIGATOR_337] (BMA) for 
correlatives/exploratory: see Table  9  
• GVHD monitoring  
• Chimerism, immune reconstitution  
• Monitor adverse events  
• Concomitant medications  
 
7.1.4  Confirmation  to Proceed to APR -246 and Azacitidine Treatment  (Day  30 
to 100)  
• Bone marrow exam, including cytomorphology, cytogenetic assessment, and 
flow cytometry analysis . 
• Engraftment is defined as ANC≥500/μL and platelets ≥ [ZIP_CODE]/μL on 3 
consecutive measurements (each occurring at least 1 day apart). The patient 
must not have had a platelet transfusion within [ADDRESS_769040] 
measurement.  
• Once this BM biopsy confirms CR and all other eligibility is confirmed, the 
patient must start  APR-[ADDRESS_769041] be administered no more than 
28 days after confirmation.  
 
7.2.1  Cycle 1, Day 1  
• APR-246 (administered Days 1 -4) 
• Azacitidine ( administered Days 1 -5) 
• PK sampling Day [ADDRESS_769042] -dosing : see Section 8.4 
• ECGs; see Table 7. 
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769043] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  53 of 81 28 October 2021  
Confidential - Entire Page  • Adverse events  
• Concomitant medications  
 
7.2.2  Cycle 1, Days 2, 3, 4, 5  
• APR-246 (administered Days 1 -4) 
• Azacitidine (administered Days 1 -5) 
• Additional ECG monitoring in s elect patients; see Section 6.2 
• PK sampling predose Day 2: see Section 8.4 
• Adverse events  
• Concomitant medications  
 
7.2.3  Cycle 1, Days 7, 14, 21  
• Vital Signs  
• CBC 
• CMP  
• Adverse events  
• Concomitant medications  
 
7.2.4  Cycle 1, Day 28  
• Physical exam with Weight  
• Vital signs  
• CBC 
• CMP  
• GVHD monitoring  
• Adverse events  
• Concomitant medications  
• Disease assessment (blood)  
 
7.2.5  Cycle s 2-4, Day 1 (Day 29 of prior cycle)  
First dose of next cycle may be delayed up to 4 weeks.  
• APR-246 (administered Days 1 -4) 
• Azacitidine (administered Days 1 -5) 
• Physical exam with Weight ; Does not need to be repeated if done within 3 days 
prior  
• Vital signs ; Does not need to be repeated if done within 3 days prior  
• CBC; Does not need to be repeated if done within [ADDRESS_769044] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  54 of 81 28 October 2021  
Confidential - Entire Page  • CMP ; Does not need to be repeated if don e within 3 days prior  
• ECGs; see Table 7. 
• Adverse events  
• Concomitant medications  
 
7.2.6  Cycle s 2-4, Days 2, 3, 4, 5  
• APR-246 (administered Days 1 -4) 
• Azacitidine (administered Days 1 -5) 
• Additional ECG monitoring in select patients; see Section  6.2 
• Adverse events  
• Concomitant medications  
 
7.2.7  Cycle s 2-4, Day 14 
• CMP  
• Adverse events  
• Concomitant medications  
 
7.2.8  Cycle s 2-4, Day 28  
• Physical exam with Weight  
• Vital signs  
• CBC 
• CMP  
• GVHD monitoring  
• Adverse events  
• Concomitant medications  
• Disease assessment, blood every cycle, bone marrow end of Cycle/Month 3  
• Chimerism, end of Cycle/Month 3  
 
7.2.9  Cycles 5-12, Day 1 (Day 29 of prior cycle)  
First dose of next cycle may be delayed up to 4 weeks.  
• APR-246 (administered Days 1 -4) 
• Azacitidine (administered Days 1 -5) 
• Physical exam with Weight; Does not need to be repeated if done within 3 days 
prior  
• Vital signs; Does not need to be repeated if done within 3 days prio r 
• CBC; Does not need to be repeated if done within [ADDRESS_769045] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  55 of 81 28 October 2021  
Confidential - Entire Page  • CMP ; Does not need to be repeated if done within 3 days prior  
• Adverse events  
• Concomitant medications  
 
7.2.10  Cycle s 5-12, Days 2, 3, 4, 5  
• APR-246 (administered Days 1 -4) 
• Azacitidine (administered Days 1 -5) 
• Additional ECG monitoring in select patients; see Section 6.2 
• Adverse events  
• Concomitant medications  
 
7.2.11  Cycles 5-12, Day 14 
• CMP  
• Adverse events  
• Concomitant medications  
 
7.2.12  Cycles 5-12, Day 28  
Every cycle:  
• Physical exam with Weight  
• Vital signs  
• CBC 
• CMP  
• GVHD evaluation  
• Adverse events  
• Concomitant medications  
• Disease assessment, blood  
 
Additionally, Every 3 cycles/months:  
• Disease assessment, bone marrow end of Cycle/Month 6, 9, [ADDRESS_769046] 
assessment and correlatives/exploratory (per Section 8.5) when bone 
marrow is sampled for disease assessment.  
• Chimerism, end of Cycle/Month 6, 9, 12  
 
Additionally, Every 6 cycles/months:  
• Immune reconstitution, end of Cycle/Month 5, [ADDRESS_769047] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  56 of 81 28 October 2021  
Confidential - Entire Page   
7.3 End of Treatment Visit  
Patients discontinuing study early should complete their end of treatment  (EOT)  visit 
within [ADDRESS_769048] (the last day of post -transplant window 
eligibility requirement ). 
 
The following should be performed at EOT:  
• Disease assessment  (blood and bone marrow)  
• Vital signs  
• CBC 
• CMP  
• ECGs; see Table 7. 
• Pregnancy test (women of child -bearing potential only)  
• Adverse events  
• Concomitant medications  
 
7.[ADDRESS_769049] dose.  
• Adverse events  
• Concomitant medications  
 
7.[ADDRESS_769050] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_769051] completed 1 cycle of APR -246 and azacitidine combination 
therapy. The Committee will decide if it is appropriate to continue at the current 
dose; or, in the event of the combination is not tolerated (e.g. patients experience 
dose limiting toxicity) the dose of APR -246 will be reduced for subsequent enrolled 
patients.  
 
Adverse events and lab values will be reviewed. No formal analysis is planned.  
 
8.1.3  Reporting of Adverse Events  
[IP_ADDRESS]  Adverse Events  
An adverse event (AE) is any untoward medical occurrence in a patient or clinical  
investigation subject administered a pharmaceutical product that does not 
necessarily have a causal relationship with the treatment.  An adverse event can be 
any unfavorable and unintended sign (including a laboratory finding), symptom or 
disease temporal ly associated with the use of a medicinal (investigational) product, 
whether or not related to the medicinal (investigational) product.  
 
The AE reporting period starts from the day of signing consent. If an AE occurs before 
the first dose of study drug it  will be considered a non -treatment emergent AE. All 
AEs will be collected for [ADDRESS_769052] dose of study drug ; see Section  8.1.4  
for GVHD reporting . 
 
At each evaluation patients should be interviewed in a non -directed manner to elicit 
potential adverse reactions from the patient.  The occurrence of an adverse event 
will be based on changes in the patient’s physical examination, laboratory results, 
and/or signs and symptoms.  
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769053] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  58 of 81 28 October 2021  
Confidential - Entire Page   
All adverse events (except grade 1 and 2 laboratory abnormalities that do not require 
an intervention), regardless of causal relationship, are to be recorded in the case 
report form and source documentation.  The Investigator must determine the 
intensity of any adverse events according to the NCI Common Terminology Criteria 
for Adverse Events (CTCAE) Version 5.0 ( see 
https://ctep.cancer.gov/protocoldev elopment/ electronic_applications/ctc.htm#ctc_50 ) and 
their causal relationship. Those AEs not covered by [CONTACT_427686]:  
 
1. Mild: Discomfort noticed, but no disruption of normal daily activity. 
Prescription drug not ordinarily needed for relief of symptom but may be 
given because of personality of patient.  
 
2. Moderate: Discomfort sufficient to reduce or affect normal daily activity. 
Patient is able to continue in study; treatment for symptom may be needed.  
 
3. Severe : Incapacitating, severe discomfort with inability to work or to perform 
normal daily activity. Severity may cause cessation of treatment with test drug; 
treatment for symptom may be given and/or patient hospi[INVESTIGATOR_057].  
 
4. Life-Threatening: Symptom(s) place  the patient at immediate risk of death 
from the reaction as it occurred; it does not include a reaction that, had it 
occurred in a more serious from, might have caused death.  
 
5.  Fatal: Event caused the death of the patient.  
 
Adverse events will be foll owed until resolution or stabilization while the patient 
remains on -study.  Once the patient is removed from study, events thought to be 
related to the study medication will be followed until resolution or stabilization, 
unless, in the Investigator’s opi[INVESTIGATOR_584946]’s underlying disease, or until the patient starts a new treatment regimen or 
the patient is lost to follow -up. 
 
[IP_ADDRESS]  Attribution Definitions  
An adverse event is considered to be associated with the use of t he Investigational 
agent if the attribution is determined as possible, probable or definite. Attribution of 
AEs will be recorded in the CRF as:  
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769054] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  59 of 81 28 October 2021  
Confidential - Entire Page  • Unrelated: The AE is clearly NOT related to the study treatment.  
• Unlikely: The AE is doubtfully related to the s tudy treatment.  
• Possible: The AE may be related to the study treatment.  
• Probable: The AE is likely related to the study treatment.  
• Definite: The AE is clearly related to the study treatment.  
 
[IP_ADDRESS]  Definition of an Unexpected Adverse Event  
An unexpected adverse event is defined as any adverse drug experience, the 
specificity or severity of which is not consistent with the current Investigator 
Brochure; or, if an Investigator Brochure is not available, the specificity or severity of 
which is not consistent with the risk information described in this protocol or in the 
regulatory agency study authorization application.   
 
Unexpected, as used in this definition, refers to an adverse drug experience that has 
not been previously observed (e.g., in cluded in the Investigator Brochure) rather than 
from the perspective of such experience not being anticipated from the 
pharmacological properties of the pharmaceutical product.  
 
8.1.4  GVHD Adverse Event Reporting  
All occurrences of GVHD will be reported as Adve rse Events (or SAEs), regardless of 
their start date in  relation to study drug. Acute GVHD will be followed until resolution, 
or until further improvement is no longer expected. Chronic GVHD events will be 
collected for [ADDRESS_769055] dose of study  drug .  
 
GVHD evaluation and grading will be performed per Harris 2016 ( APPENDIX C) and 
Jagasia 2015  (APPENDIX D).25,26 
 
[IP_ADDRESS]  Serious Adverse Event (SAE)  
A serious adverse event is d efined as any untoward medical occurrence that at any 
dose:  
 
1. Results in death,  
 
2. Is life -threatening (i.e., the patient was at risk of death at the time of the event. 
It does not refer to an event which hypothetically might have caused death if 
it was  more severe),  
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769056] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  60 of 81 28 October 2021  
Confidential - Entire Page   
3. Requires in -patient hospi[INVESTIGATOR_122948], disease staging/re -staging procedures, 
or catheter placement unless associated with other serious events , 
 
4. Results in persistent or significant disability/incapacity, or  
 
5. Is a congenital anomaly/birth defect.  
 
Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_584947] w hen, based on 
appropriate medical judgment, they may jeopardize the patient or subject and may 
require medical or surgical intervention to prevent one of the outcomes listed above.  
 
[IP_ADDRESS]  Pregnancy  
Any pregnancy diagnosed during the study, or that occurs within [ADDRESS_769057] becomes aware of a pregnancy or its outcome. This will 
be performed by [CONTACT_122978] a Pregnancy Form and emailing it or 
faxing it to the  
  
 
Any pregnancy complication, spontaneous abortion, elective termination of a 
pregnancy for medical reason s, outcome of stillbirth, congenital anomaly/birth 
defect, or serious adverse event in the mother will be recorded as an SAE and will be 
reported as described in Section [IP_ADDRESS] .  
 
[IP_ADDRESS]  Reporting of Serious Adverse Events  
Adverse events classified as serious require expeditious handling and reporting to 
o comply  with regulatory requirements.  
 

Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769058] -transplant  
 maintenance in AML/MDS  
1172_CSP 3.0  61 of 81 28 October 2021  
Confidential - Entire Page  For any serious adverse event (SAE) that occurs from APR-[ADDRESS_769059] study drug administration, regardless of any opi[INVESTIGATOR_584948]; or if any SAE that the Investigator feels is 
related to the study drug occurs later than [ADDRESS_769060] study drug 
administration, the  
 
 
 
 
 
All SAEs require that a Serious Adverse Event Repor t Form be completed and sent  as 
a PDF via email (preferred method) or faxed to  at the address below within 
24 hours of becoming aware of the event.  
In the [LOCATION_003], SAEs will be reported to:   
 
 
 
[IP_ADDRESS]  Safety Monitoring Committee  
The Safety Monitoring Committee, consisting of the Principal Investigator [INVESTIGATOR_584949](s)  (if different from the Principal Investigator), S ponsor and 
Medical Monitor, will perform a safety  evaluation after the first [ADDRESS_769061] 
completed 1 cycle of APR -246 and azacitidine combination therapy.  Afterwards, 
safety will continue to be monitor ed and discussed during the regular study status 
meetings per the scheduled plan.   
8.2 Efficacy Assessments  
Treatment response will be assessed by [CONTACT_584975]/BMA and flow cytometry at the 
protocol -specified timepoints. In the LTFU period, assessments may be  performed 
per institutional standard frequency.  
CBC and differential will also be used to assess the presence of blasts in PB, as well 
as the extent of hematopoietic recovery.  

Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769062] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  62 of 81 28 October 2021  
Confidential - Entire Page  Disease assessment, according to the Investigator,  will be determined at each  
assessment according to the modified  International Working Group (IWG) response 
criteria appropriate to the patient's underlying disease  (Cheson 2003, 2006) .27, 28 
 
8.3 ECGs  
For all patients, ECGs will be read at the timepoints listed in Table 7. Patients with 
screening or any pre -dose QTc of 450 ≤ QTc <[ADDRESS_769063] to more 
intense ECG monitoring  described in Section 6.2. 
 
Table 7: ECG Timepoints  
Schedule  # of ECGs  Timing  
Pre screening  Triplicate  N/A 
Post -transplant, pre -
screening (before APR -
246)  Triplicate  N/A 
Cycle 1, Day 1  Single or 
replicate  Pre-dose; EOI/ Post dose (4 hrs. after SOI; +/- 30 min.)  
Cycle 2, Day 1  Pre-dose; EOI/ Post dose (4 hrs. after SOI; +/- 30 min.)  
Cycle 3, Day 1  Pre-dose; EOI/ Post dose (4 hrs. after SOI; +/- 30 min.)  
Cycle 4, Day 1  Pre-dose; EOI/ Post dose (4 hrs. after SOI; +/- 30 min.)  
EOT N/A 
EOT: end of treatment ; SOI=start of infusion; EOI=end of infusion  
 
8.4 Pharmacokinetics  
PK blood samples will be collected per Table 8. 
 
Table 8: PK Timepoints  
 
Cycle  
Study  
Day  
Nominal time  
Time-point 
Cycle 1   
Day 1 0 hours 0-2 hrs prior to APR-246 infusion 
0.75 hours  45 minutes after start of infusion  
4 hours +/-[ADDRESS_769064] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  63 of 81 28 October 2021  
Confidential - Entire Page   
8.5 Correlatives/Exploratory Studies  
Table  9: Biosampling Timepoints  
Cycle  Timepoint(s)  Window  Blood  and 
Bone 
Marrow  
for 
chimerism  Blood for 
immune 
reconstitution  BMA 
for 
MRD  BM 
biopsy 
for IHC  
pre-
transplant  Baseline  -[ADDRESS_769065] -
transplant, 
before APR -
246/ 
azacitidine  per institutional 
standard of care  ◊ Day [ADDRESS_769066] -
transplant ◊ X X   
APR-246/ 
azacitidine 
treatment 
period  Baseline ¥ -28 to -1 prior 
to starting 
APR-246 and 
azacitidine    X X 
APR-246/ 
azacitidine 
treatment 
period  end of C3, 6, 9, 12  
(or EOT) ¥ 
 
 up to 14  days  X  X X 
APR-246/ 
azacitidine 
treatment 
period  end of C5 and 11  +/- 3 days   X   
◊ A patient could proceed to APR -246/azacitidine treatment as early as Day [ADDRESS_769067] -
transplant. Therefore sampling frequency will depend on institutional practices and 
patient status.  
¥ Bone marrow aspi[INVESTIGATOR_584950].  
 
8.5.1  Donor/R ecipi[INVESTIGATOR_584951] -transplant donor/recipi[INVESTIGATOR_584952] 3 months by [CONTACT_584976]3/CD33 cells according to local practice.  Refer to Table  9. 
 
8.5.[ADDRESS_769068] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_769069] by [CONTACT_584977]/measurable residual disease (MRD) is monitored by a high -sensitivity NGS 
panel, including TP53 , at a central laboratory. T he TP53  variant allele frequency (VAF) 
will be determined as a measure of MRD. Bone marrow aspi[INVESTIGATOR_584953]-HSCT baseline, post -HSCT baseline, C3, C6, C9 and C12. Material for additional 
explorative biomarker research will be collected fro m the same samples.  Refer to 
Table  9. 
 
8.5.4  p53 IHC  
p53 protein expression as marker for cells with TP53  mutation will be monitored by 
[CONTACT_9064] (IHC) at a central laboratory. Bone marrow biopsy cores  will 
be obtained at pre -HSCT baseline, post -HSCT baseline, C3, C6, C9 and C12.  Refer to 
Table  9. 
 
8.5.[ADDRESS_769070] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  65 of 81 28 October 2021  
Confidential - Entire Page   
9.0 STATISTICS  
Demographic and clinical variables for the study patients will be summarized using 
descriptive statistics (mean, standard deviation, median, inter -quartile range, range, 
frequency counts and percentages). Safety and efficacy da ta will be analyzed overall 
as well as separately for each dose cohort when appropriate.  
 
9.1 Safety  
Safety data including adverse events, vital signs, laboratory data, ECG, physical exam 
will be tabulated for the Safety Evaluable population  which is al l subje cts who are 
registered on the study and received any dose of APR -246 or azacitidine. Adverse 
events will be tabulated by [CONTACT_6764], preferred term, severity, and relationship 
to study drugs. The tabulation of laboratory parameters will include the normal  
ranges for each parameter.  Each value will be classified as falling above, below, or 
within the normal range.  Laboratory parameters will also be tabulated by [CONTACT_584978]-CTCAE v5 severity grade. Incidence and grade of acute and chronic GVHD at 1 -
year an d cumulative will be summarized by [CONTACT_6227] (%) of subjects for each dose 
level and overall.  
 
9.2 Sample Size  
The primary endpoint of the study is the relapse -free survival (RFS) at 12 months. The 
primary analysis will be done using the Kaplan -Meier method. Base d upon the 
published data, the risk of relapse and non -relapse mortality in TP53  mutated MDS 
is assumed to be ~40% and ~30% at 1 year, respectively. Thus the assumptions used 
for the sample size determination are :  
• the null hypothesis: the RFS at 1 year is 30%,  
• the alternative hypothesis: the RFS at 1 year is 50% or higher,  
• accrual time: 24 months,  
• follow -up time: 12 months,  
• the RFS follows the exponential distribution.  
 
With a one -sided significance level of 10%, 31 subjects will provide 90.1% power to 
test the null hypothesis against the alternative. The expected number of events 
during the study is [ADDRESS_769071] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_769072] one efficacy assessment, or had relapse/progression.   
 
9.3.[ADDRESS_769073], or death, whichever occurs earlier. If patients discontinued 
treatment due to toxicity, and withdrew consent without relapse disease (RD) or 
death at the time of data cut off, RFS will be censored at the date of the last 
assessment.  
 
RFS will be analyzed using K aplan -Meier methodology. Kaplan -Meier curves will be 
plotted. Median relapse -free survival will be estimated and their 95% confidence 
intervals based on Brookmeyer -Crowley methodology will be calcul ated.  
 
9.3.2  Overall Survival  
Overall survival (OS) is defined as the number of days from the date of registration 
to the date of death, irrespective of the cause. In the event of no death, overall 
survival will be censored at the last known alive date.  
 
OS will be analyzed using the similar methods as RFS. 
 
9.3.3  Non -Relapse Mortality  
Non -relapse mortality (NRM) is defined as time to deaths without 
relapse/ recurrence. Deaths from any cause without prior progression are events. 
Events related to the disease such as relapse  and progression are competing events . 
Patients lost to follow ‐up are censored.  
 
NRM will be analyzed using the  similar methods as RFS. 
 
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769074] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  67 of 81 28 October 2021  
Confidential - Entire Page  9.3.4  Time to Progression (TTP)  
Time to progression or relapse is time to first event related to the d isease, such as 
disease progression, disease relapse/recurrence, death from disease progression, 
and/or initiation of any therapy given to prevent relapse. Deaths without prior 
relapse/recurrence (i.e. , NRM) are competing events.  
 
TTP will be analyzed usin g the similar methods as RFS.  
 
9.3.5  Event -Free Survival (EFS)  
EFS is defined as from registration to the first of: morphologic disease relapse, death 
from any cause, reappearance of a pre -transplant cytogenetic alteration, DLI for the 
purpose of treating MDS/AM L, or institution of anti -MDS/AML therapy.  
 
 
 
 
 
  
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769075] -transplant  
 maintenance in AML/MDS  
1172_CSP 3.[ADDRESS_769076] manager, or designee, will make an initiation site visit to each institution 
to review the protocol and its requirements with the Investigator(s), inspect the drug 
storage area, fully inform the Investigator of his/her responsibilities and the 
procedures for assuring adequate and correct documentation.  During the initiation 
site visit the case report forms (CRFs) will be reviewed. O ther pertinent study 
materials will also be reviewed with the Investigator’s research staff.  During the 
course of  the study, the monitor will make regular site visits in order to review 
protocol compliance, examine CRFs and individual subject’s medical records and 
assure that the study is being conducted according to pertinent regulatory 
requirements. All CRF entries  will be verified with source  documentation . The review 
of medical records will be done in a manner to assure that patient confidentiality is 
maintained.  
10.2 Curricula Vitae and Financial Disclosure of Investigators 
All Principal Investigators will be requi red to provide a current signed and dated 
curriculum vitae, a completed FDA Form 1572  and a  financial disclosure statement 
to . All Sub -investigators will be required to provide a current curriculum 
vitae and a financial disclosure statement to . 
10.3 Protocol Modifications  
No modification of the protocol should be implemented without the prior written 
approval of the Sponsor or the Sponsor’s representative (  Any such 
changes which may affect a patient’s treatment or informed consent, especially those 
increasing potential risks, must receive prior approval by [CONTACT_1201]/IEC. The exception 
to this is where modifications are necessary to eliminate an immediate hazard to trial 
subjects, or when the change involves only logistical or administr ative aspects of the 
trial (e.g. , change in monitor, change in telephone number). Other administrative 
revisions which may impact the clinical portion of a study will be duly reported to the 
IRB/IEC by [CONTACT_079].  
10.4 Publication Policy  
The In vestigator agrees to inform the Sponsor of any publication or presentations on 
the study. All manuscripts, abstracts or presentations (in outline form with copi[INVESTIGATOR_584954] s, Inc.  
Protocol Number A19 -[ADDRESS_769077] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  69 of 81 28 October 2021  
Confidential - Entire Page  slides if available) will be submitted to the Sponsor and x at least [ADDRESS_769078] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_769079] be signed, 
witnessed and dated. The informed consent form will contai n all the Essential 
Elements of Informed Consent set forth in 21  CFR, Part 50, the European Union 
Directive 2001/20/EC and its associated Detailed Guidances, European Union GCP 
Directive 2005/28/EC, the ICH Guideline for Good Clinical Practice, Section  4.8, and 
the terms of the Declaration of Helsinki ( 2013 ). Copi[INVESTIGATOR_584955]’s study file, as well as the patient’s 
medical record if in conformance with the institution’s Standard Operat ing 
Procedures.  
 
In cases where minors or incapacitated subjects are to be included, two sets of 
information sheets might be needed according to national regulations. In addition to 
the information given to the patient’s parent or legal representative, the patient 
should be given information according to his/her capacity to understand.  This 
information should include, where appropriate, a statement that the patient’s 
decision not to participate or to withdraw from a trial will be respect ed, even if 
consent is given by [CONTACT_7071]/legal representative.  
 
11.[ADDRESS_769080]/Independent Ethics Committee  
The study will not be initiated without approval of the appropriate Institutional 
Review Board/Independent Ethics Committee (IRB/IEC) and compliance with all 
administrative requirements of the governing body of the institution.  This protocol, 
consent procedures, and any amendments must be approved by [CONTACT_1201]/IEC in 
compliance with current regulations of the FDA and the European Union as  
applicable and in accordance with ICH/GCPs.  A letter of approval will be sent to the 
Sponsor prior to initiation of the study and when any subsequent modifications are 
made.  The IRB/IEC will be kept informed by [CONTACT_737],  or the 
Sponsor,  as required by [CONTACT_2091], as to the progress of the study as well 
as to any serious and unexpected adverse events.  
 
11.[ADDRESS_769081] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  71 of 81 28 October 2021  
Confidential - Entire Page  patient numbers; patients should not be identified by [CONTACT_2300].  In accordance with 
local, national or federal regulations, the Investigator will allow the Sponsor or 
designee personnel access to al l pertinent medical records in order to verify the data 
gathered on the case report forms and to audit the data collection process.  
Regulatory agencies such as the US Food and Drug Administration (FDA) and the [LOCATION_006] 
Medicine and Healthcare Products Regulator y Agency (MHRA) may also request 
access to all study records, including source documentation for inspection.  Clinical 
information will not be released without the written permission of the patient as 
outlined in the patient consent form.  
 
  
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769082] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_769083] KEEPI[INVESTIGATOR_1645]  
12.1 Recording of Data  
Data collected during the study will be entered in the patient’s Case Report Form 
(CRF) by [CONTACT_54110]. The staff will keep records of the patient’s visit 
in the files considered as source documents f or the site, e.g., hospi[INVESTIGATOR_3853], research 
chart. The Investigator will be responsible for the recording of all data on the CRF  and 
for submitting the data to the Sponsor or their designee in a timely manner . Should 
any value be significantly different from normal, the Investigator will comment in the 
appropriate sections provided in the  CRF.   
 
The Investigator will provide access to his/her original records to permit a 
representative from the Sponsor to verify the proper transcription of data.  To 
facilitate photocopying, entries must be recorded legibly in black ink only.  Erroneous 
entries will be crossed out with a single line, so as to remain legible.  The correct value 
will be entered above the error and then initialed and dated by [CONTACT_584979].  
 
12.[ADDRESS_769084]’s medical files should be retained in accordance with applicable legislation 
and in  accordance with the maximum period of time permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.  
 
  
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769085] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  73 of 81 28 October 2021  
Confidential - Entire Page  13.0 REFERENCES  
 
1 Margulies M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high -density 
pi[INVESTIGATOR_584956]. Nature 2005;437:376 -80. 
2 Malcovati L, Hellstrom -Lindberg E, Bowen D, et al. Diagnosis and treatment of primary 
myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 
2013;122:2943 -64. 
3 Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver 
mutations in myelodysplastic syndromes. Blood 2013;122:3616 -27; quiz 99.  
[ADDRESS_769086] of Point Mutations in Myelodysplastic 
Syndromes. New England Journa l of Medicine 2011;364:2496 -506.  
5 Kulasekararaj AG, Smith AE, Mian SA, et al. TP53  mutations in myelodysplastic syndrome are 
strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. British 
journal of haematology 2013;16 0:660 -72. 
6 Bally C, Ades L, Renneville A, et al. Prognostic value of TP53  gene mutations in myelodysplastic 
syndromes and acute myeloid leukemia treated with azacitidine. Leukemia research 2014;38:751 -5. 
7Mallo M, Del Rey M, Ibanez M, et al. Response to l enalidomide in myelodysplastic syndromes with 
del(5q): influence of cytogenetics and mutations. British journal of haematology 2013;162:74 -86.  
8 Takahashi K, Patel K, Bueso -Ramos C, et al. Clinical implications of TP53  mutations in 
myelodysplastic syndromes treated with hypomethylating agents. Oncotarget 2016;7:[ZIP_CODE] -87. 
9 Ferrari A, Papayannidis C, Baldazzi C, et al. Leukemia Associated TP53  Mutat ions in AML Patients 
ARE Strongly Associated with Complex Karyotype and Poor Outcome. Blood 2014;124:2379.  
[ADDRESS_769087] Adverse Outcome in Patients 
Undergoing Allogeneic Hematopoietic Stem Cell Transp lant. Blood 2016;128:3481.  
[ADDRESS_769088] poor outcome in patients with 
myelodysplastic syndrome after hematopoietic stem -cell transplantation. Journal of clinical oncology 
: official journal of the Ame rican Society of Clinical Oncology 2014;32:2691 -8. 
12 Lindsley RC, Saber W, Mar BG, et al. Prognostic Mutations in Myelodysplastic Syndrome after 
Stem -Cell Transplantation. New England Journal of Medicine 2017;376:536 -47. 
13 Fenaux P, Mufti GJ, Hellstrom -Lindberg E, et al. Efficacy of azacitidine compared with that of 
conventional care regimens in the treatment of higher -risk myelodysplastic syndromes: a 
randomised, open -label, phase III study. The Lancet Oncology 2009;10:[ADDRESS_769089] count acute myeloid 
leukemia. Journal of clinical oncology : official journal of the American Society of Cli nical Oncology 
2010;28:[ADDRESS_769090]: a retrospective analysis. Bone 
marrow transplantation 2010; 45:872 -6. 
16 Jabbour E, Giralt S, Kantarjian H, et al. Low -dose azacitidine after allogeneic stem cell 
transplantation for acute leukemia. Cancer 2009;115:1899 -905.  
17 de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low -dose azacitidine after allogeneic 
hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or 
myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010;116:[ADDRESS_769091] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_769092] -Transplantation 
Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial. Biology 
of Blood and Marrow Transplantation 2016;22:385 -90. 
19 By[CONTACT_427695], Issaeva N, Selivanova G, Wiman KG. Mutant p53 -dependent growth s uppression 
distinguishes PRIMA -1 from known anticancer drugs: a statistical analysis of information in the 
National Cancer Institute database. Carcinogenesis 2002;23:2011 -8. 
20 Nahi H, Mer up M, Lehmann S, et al. PRIMA -1 induces apoptosis in acute myeloid le ukaemia cells 
with p53 gene deletion. British journal of haematology 2006;132:230 -6. 
21 APREA THERAPEUTICS. INVESTIGATOR’S BROCHURE (IB) APR -246.  
22 Lambert JM, Gorzov P, Veprintsev DB, et al. PRIMA -1 reactivates mutant p53 by [CONTACT_584980]. Cancer cell 2009;15:376 -88. 
23 Peng X, Zhang MQ, Conserva F, et al. APR -246/PRIMA -1MET inhibits thioredoxin reductase 1 and 
converts the enzy me to a dedicated NADPH oxidase. Cell death & disease 2013;4:e881.  
24 Lehmann S, By[CONTACT_584981], Ali D, et al. Targeting p53 in vivo: a first -in-human study with p53 -targeting 
compound APR -246 in refractory hematologic malignancies and prostate cancer. Journal of  clinical 
oncology: official journal of the American Society of Clinical Oncology 2012;30:[ADDRESS_769093] Disease 
Clinical Data Collection: A report from the Mount Sinai Acut e GVHD International Consortium. Biol 
Blood Marrow Transplant 2016 Jan;22(1):[ADDRESS_769094] disease: I. The 2014 Diagnosis and Staging Working Group 
report. Biology of Blood and Marrow Transplantation. 2015 Mar 1;21(3):389 -401.  
27 Cheson BD, et al. Clinical application and proposa l for modification of the International Working 
Group (IWG) response criteria in myelodysplasia. Blood 2006:108.2:419 -425.  
28 Cheson BD, et al. Revised Recommendations  of the International Working Group for Diagnosis, 
Standardization of Response Criteria, T reatment Outcomes, and Reporting Standards for 
Therapeutic Trials in Acute Myeloid Leukemia. Journal of clinical oncology 2003;21(24):[ADDRESS_769095] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_769096] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  76 of 81 28 October 2021  
Confidential - Entire Page  APPENDIX B- SCHEDULE OF EVENTS  
Table 10: Pre-Screen, APR -246/azacitidine Screening, Cycles 1 -4 (Treatment Period)  
 Pre-
screen  HSCT  
 Post HSCT/ 
Screening 
Period APR -
246/AZA (3)  APR -246/AZA Treatment  
Cycle 1  APR -246/AZA Treatment  
Cycle s 2, 3, 4  
(Cycles 5+; see Table 11) 
Day -[ADDRESS_769097]  1 (first dose)  2, 3, 
4 5 7, 
14, 
21 28 1 (D29 
prior 
cycle)  2, 3, 
4 5 14 28 
Window     NMT 28 days after 
engraftment 
confirmation    +/- 3 +/-3 
* +28   +/-3 +/-3 * 
Informed Consent  X  X           
HSCT -eligibility  X             
TP53  mutation confirmation  X             
Engraftment confirmation    X (3)            
APR-246     X X    X X    
Azacitidine     X X X X X X 
APR-246/AZA Eligibility    X (4)            
Karnofsky Performance 
Status    X           
Medical  History and 
Transplant Details    X (4)            
Physical Exam with Weight    X (5)      X X (5)     X 
Vital Signs    X (5)     X X X (5)     X 
CBC   X (5)     X X X (5)     X 
CMP    X (5)     X X X (5)    X X 
Cardiac function (ECG)  X  X (5) (7)  X (7)  X (7)     X (7)  X (7)     
Pregnancy Test (1)  X  X (5)            
Disease Assessment  (9) X  X (4)      X (9)      X (9)  
BM/BMA for Correlatives/ 
exploratory (2)  X (2)   X (2)           X (2)  
GVHD monitoring    X     X     X 
Blood sample (chimerism)              Cycle 3  
(8) 
Blood sample for flow 
(immune  reconstitution)    X (4)            
PK sampling (blood)     X (6)  X (6)          
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769098] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.[ADDRESS_769099]/ 
Screening 
Period APR -
246/AZA (3)  APR -246/AZA Treatment  
Cycle 1  APR -246/AZA Treatment  
Cycle s 2, 3, 4  
(Cycles 5+; see Table 11) 
Day -[ADDRESS_769100]  1 (first dose)  2, 3, 
4 5 7, 
14, 
21 28 1 (D29 
prior 
cycle)  2, 3, 
4 5 14 28 
Window     NMT 28 days after 
engraftment 
confirmation    +/- 3 +/-3 
* +28   +/-3 +/-3 * 
Adverse Events    X X X X X X X X X X X 
Concomitant Medications    X X X X X X X X X X X 
 
(1) Pregnancy test applies to women of child -bearing potential only.  
(2) Bone marrow aspi[INVESTIGATOR_584957]/exploratory (per Section  8.5) when bone marrow is sampled 
for disease assessment . 
(3) APR-246/azacitidine Screening Period starts when engraftment is confirmed between  Day [ADDRESS_769101] be 
administered no more than 28 days after engraftment is confirmed.  
(4) Perform within [ADDRESS_769102] dose (Cycle 1 Day 1).  
(5) Perform within  [ADDRESS_769103] dose (Cycle 1 Day 1); for Cycle 2+, do not need to repeat if done within 3 days prior to dosing.  
(6) PK: see Section 8.4. 
(7) Day 1 ECGs  for all patients; se e Table 7.  Day 2, 3, [ADDRESS_769104] patients; see Section 6.2. 
(8) CD3/CD33  in the blood should be done every 3 months same time marrows for disease assessment are being done.  Additionally,  whole 
bone marrow chimerism should be done from the marrow every 3 months collected at same time disease assessment labs are done  
(9) Diseas e assessment by [CONTACT_584982]. Response assessment based on CBC may utilize the most recently 
available bone marrow results. Disease assessment by [CONTACT_584983] C3. 
* Up to [ADDRESS_769105] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  78 of 81 28 October 2021  
Confidential - Entire Page  Table 11: Cycle 5-12 (Treatment Period) , EOT, 30 day Safety FUV, LTFU  
 APR -246/AZA Treatment  
Cycles 5 - 12 EOT 
(5) Follow -up 
safety visit  Long Term 
Follow -up (6)  
Day 1 (D29 
prior 
cycle)  2, 3, 
4 5 14 28  30 +/ - [ADDRESS_769106] dose   
Window  +28   +/- 3 +/- 3 *    
         
APR-246  X X       
Azacitidine  X X X 
Physical Exam with Weight  X (3)     X    
Vital Signs  X (3)     X X   
CBC X (3)     X X   
CMP  X (3)    X X X   
Cardiac function (ECG)  X (4)  X (4)     X   
Pregnancy Test (1)       X   
Disease Assessment      X (8)  X  X (6)  
BM/BMA for Correlatives/exploratory (2)      C 6, 9, 12  (2)    
GVHD monitoring      X   X (6)  
Blood sample (chimerism) (7)      C 6, 9, 12     
Blood sample for flow (immune 
reconstitution)      C 5, 11     
Adverse Events  X X X X X X X  
Concomitant Medications  X X X X X X X  
Survival         every 6 months  
(1) Pregnancy test applies to women of child -bearing potential only.  
(2) Bone marrow aspi[INVESTIGATOR_584957]/exploratory (per Section  8.5) when bone marrow is sampled 
for disease assessment . 
(3) Do not need to repeat if done within 3  days prior to dosing.  
(4) After Cycle 4, perform a dditional ECG monitoring  in select patients ; see Section 6.2. 
(5) EOT: see Section 7.3. 
(6) LTFU applies to all patients. LTFU via phone call for survival will occur every [ADDRESS_769107] of care, the site should report results to the sponsor until relapse is 
documented.  
(7) CD3/CD33 in the blood should be done every 3 months same time marrows for disease assessment are being done.  Additionally,  whole 
bone marrow chimerism should be done from the marrow every 3 months collected at same time disease assessment labs are done  
(8) Disease assessment by [CONTACT_584982]. Response assessment based on CBC may utilize the most re cently 
Aprea Therapeutic s, Inc.  
Protocol Number A19 -[ADDRESS_769108] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  79 of 81 28 October 2021  
Confidential - Entire Page  available bone marrow results. Disease assessment by [CONTACT_584983] C3.  
* Up to [ADDRESS_769109] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  80 of 81 28 October 2021  
Confidential - Entire Page   
APPENDIX C- ACUTE GVHD GRADING SCALE  
GVHD Target Organ Staging  
Stage  Skin (Active Erythema 
Only)  Liver (bilirubin)  Upper GI  Lower GI (stool 
output/day)  
0 No active (erythematous) 
GVHD rash  < 2 mg/dl  No intermittent nausea, 
vomiting, or anorexia  <500 mL/day or <3 
epi[INVESTIGATOR_1841]/ day 
1 Maculopapular rash 
<25% BSA  2-3 mg/dl  Persistent nausea, vomiting or 
anorexia  500-999 mL/day or 3 -4 
epi[INVESTIGATOR_1841]/day  
2 Maculopapular rash 25% -
50% BSA  3.1-6 mg/dl   1000 -1500 mL/day or 5 -7 
epi[INVESTIGATOR_1841]/day  
3 Maculopapular rash 
>50% BSA  6.1-15 mg/dl   >1500 mL/day or >7 
epi[INVESTIGATOR_1841]/day  
4 Generalized 
erythroderma (>50% BSA) 
plus bullous formation 
and desquamation >5% 
BSA >15 mg/dl   Severe abdominal pain 
with or without ileus or 
grossly bloody stool 
(regardless of stool 
volume)  
 
Overall clinical grade (based on most severe target organ involvement):  
Grade 0:  No Stage 1 -4 of any organ.  
Grade 1:  Stage 1 -2 skin without liver, upper GI, or lower GI involvement.  
Grade 2:  Stage 3 rash and/or stage 1 liver and/or stage 1 upper GI and/or stage 1 lower GI.  
Grade 3:  Stage 2 -3 liver and/or stage 2 -3 lower GI, with stage 0 -3 skin and/or stage 0 -1 upper GI.  
Grade 4:  Stage 4 skin, liver, or lower GI involvement, with stage 0 -1 upper GI.  
Reference:   Harris AC, et al. Biol Blood Marrow Transplant 2016; 22:[ADDRESS_769110] -transplant  
 maintenance in AML/MDS  
 
1172_CSP 3.0  81 of 81 28 October 2021  
Confidential - Entire Page   
APPENDIX D- CHRONIC GVHD GRADING SCALE  
Excerpted from Jagasia 2015: The following outlines the computation of the chronic GVHD global severity scoring, which is cat egorized as 
mild, moderate, or severe.  
 
NIH Global Severity of chronic GVHD  
 
Mild chronic GVHD:  
1 or 2 organs involved with no more than score 1 plus 
Lung score 0  
 
Moderate chronic GVHD:  
[ADDRESS_769111] 1 organ (not lung) with a score of 2  
OR, 
Lung score 1  
 
Severe chronic GVHD:  
At least 1 organ with a score of 3  
OR 
Lung score of 2 or 3  
 
KEY POINTS:  
In skin: higher of the 2 scores to be used for calculating global severity.  
In lung: FEV1 is used instead of clinical score for calculating global severity.  
If the entire abnormality in an organ in noted to b e unequivocally explained by a non -GVHD documented cause, that organ is not included 
for calculation of the global severity.  
If the abnormality in an organ is attributed to multifactorial causes (GVHD plus other causes) the second organ will be used for ca lculation 
of the global severity regardless of the contributing causes (no downgrading of organ severity score).  
 